

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1-46. (Cancelled).

47. (Previously Presented) Library comprising a plurality of tagged ligands of formula I

$(\text{Lig J}_L)_m \text{ L } (\text{J}_T \text{ Tag})_m (\text{J}_T \text{ L } (\text{J}_L \text{ Lig})_m)_p$

and salts thereof wherein any optically active fluorescent ligand is present as a racemate or as one of its optically active isomers

comprising one or a plurality of same or different ligand moieties Lig each linked to one or a plurality of same or different tag moieties Tag via same or different linker moieties L and same or different linking site or linking functionality J<sub>T</sub> and J<sub>L</sub>

wherein Lig is a ligand selected from a non-peptide GPCR ligand agonist and a non-peptide GPCR ligand antagonist, wherein the Lig comprises pharmacological activity as an agonist or antagonist for GPCR receptor binding and activation or inhibition,

L is selected from amine, amide, saturated or unsaturated, substituted or unsubstituted C<sub>1-600</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, wherein optional substituents are selected from any C<sub>1-20</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine,

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

oxo, cyano and carbonyl and combinations thereof, and L is monomeric, oligomeric having oligomeric repeat of 2 to 30 or polymeric having polymeric repeat in excess of 30 up to 300;

Tag is any tagging substrate;

m are each independently selected from a whole number integer from 1 to 3;

p is 0 to 3

wherein one or more of each -Tag in one or more of each library compound is a fluorophore entity -Fl, whereby the library comprises compounds of which one or more or all of which are of formula I'



characterised in that linking is at same or different linking sites in compounds comprising different Lig, J<sub>L</sub>, L, J<sub>T</sub> and/or - Tag and is at different linking sites in compounds comprising same Lig, J<sub>L</sub>, L, J<sub>T</sub> and/or - Tag

wherein the or each Fl is selected from a red, near ir or blue dye,  
and the compound of formula I or I' retains pharmacological activity as a fluorescent GPCR ligand agonist or fluorescent GPCR ligand antagonist or GPCR receptor binding and activation or inhibition.

48. (Withdrawn-Previously Presented) Library comprising a plurality of tagged ligands of formula I



and salts thereof wherein any optically active fluorescent ligand is present as a racemate or as one of its optically active isomers

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

comprising one or a plurality of same or different ligand moieties Lig each linked to one or a plurality of same or different tag moieties Tag via same or different linker moieties L and same or different linking site or linking functionality J<sub>T</sub> and J<sub>L</sub>

wherein Lig is a ligand selected from a non-peptide GPCR ligand agonist and a non-peptide GPCR ligand antagonist, wherein the Lig comprises pharmacological activity as an agonist or antagonist for GPCR receptor binding and activation or inhibition,

L is selected from amine, amide, saturated or unsaturated, substituted or unsubstituted C<sub>1-600</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, wherein optional substituents are selected from any C<sub>1-20</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano and carbonyl and combinations thereof, and L is monomeric, oligomeric having oligomeric repeat of 2 to 30 or polymeric having polymeric repeat in excess of 30 up to 300;

Tag is any tagging substrate;

m are each independently selected from a whole number integer from 1 to 3;

p is 0 to 3

wherein one or more of each -Tag in one or more of each library compound is a fluorophore entity -Fl, whereby the library comprises compounds of which one or more or all of which are of formula I'

(LigJ<sub>L</sub>)<sub>m</sub> L(J<sub>T</sub> Fl)<sub>m</sub>(J<sub>T</sub>L(J<sub>L</sub>Lig)<sub>m</sub>)<sub>p</sub>

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

characterised in that linking is at same or different linking sites in compounds comprising different Lig, J<sub>L</sub>, L J<sub>T</sub> and/or – Tag and is at different linking sites in compounds comprising same Lig, J<sub>L</sub>, L J<sub>T</sub> and/or – Tag,

wherein the or each Fl is selected from the following dyes: Texas red™, coumarin and derivatives, Cascade Blue™, EvoBlue and fluorescent derivatives thereof, pyrenes and pyridyloxazole derivatives, the cyanine dyes, the dyomics (DY dyes and ATTO dyes) and fluorescent derivatives thereof, the Alexafluor dyes and derivatives, BDI dyes including the commercially available Bodipy™ dyes, pyrenes, anthracenes, acridines, fluorescent phycobiliproteins and their conjugates and fluoresceinated microbeads, and Texas Red derivatives, coupled to amine groups using the isocyanate, succinimidyl ester or dichlorotriazinyl-reactive groups,

and the compound of formula I or I' retains pharmacological activity as a fluorescent GPCR ligand agonist or fluorescent GPCR ligand antagonist or GPCR receptor binding and activation or inhibition.

49. (Withdrawn-Previously Presented) Library as claimed in Claim 47 wherein each compound of formula I or I' comprises one of a plurality of fluorophores and/or tags providing a library of differently fluorescently tagged ligands comprising one or a number of different fluorophores optionally of different chemical composition or spectral characteristics; and/or providing a library of differently tagged ligands including at least one fluorescently tagged ligand; alternatively each compound of formula I or I' comprises one of a plurality of precursor ligands linked each to one or a plurality of different tags providing a library of same or differently tagged ligands of plural ligand type; alternatively each compound of formula I

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

comprises one of a plurality of linkers linking a precursor ligand and at least one Tag at the same or different linking site; alternatively each compound of formula I or I' comprises the same linker linking a precursor ligand and at least one Tag at different linking sites providing a library of differently linked tagged ligands of different conformation or anticipated pharmacology and binding.

50. (Withdrawn) Library as claimed in Claim 47 comprising a plurality of compounds of one or more of formula II to III:

II       $(\text{LigJ}_L)_m L J_T \text{TagJ}_T L (J_L \text{Lig})_m$  where each m is as hereinbefore defined and is preferably 1 or 2, more preferably 1

III       $(\text{LigJ}_L)_m L (J_T \text{Tag})_m$  wherein each m is as hereinbefore defined and is preferably 1 and/or 2, more preferably

Lig J<sub>L</sub> – L – J<sub>L</sub> Tag and/or

Lig J<sub>L</sub> – L – J<sub>T</sub> Tag    and/or      Lig J<sub>L</sub> – L – J<sub>T</sub> Tag

    \J<sub>L</sub> Lig                                  \J<sub>T</sub> Tag

wherein each J<sub>L</sub> and J<sub>T</sub> comprises J as hereinbefore defined and may be same or different and may derive from functionality originally present in Lig or L and Tag or L or a combination thereof, characterised in that linking is at same or different linking sites in compounds comprising different Lig, J<sub>L</sub>, L, J<sub>T</sub> and/or Tag, and is at different linking sites in the case of any two or more compounds comprising identical Lig, J<sub>L</sub>, L, J<sub>T</sub> and/or Tag.

51. (Withdrawn-Previously Presented) Library as claimed in Claim 47 wherein each compound of formula I has verified pharmacology for binding to or inhibition of a GPCR

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

receptor including designation as agonist or antagonist and measure of affinity or inhibition, enabling quantification of results.

52. (Withdrawn-Previously Presented) Library as claimed in Claim 47 wherein Lig is selected from any compound which is effective as an agonist or antagonist for an adenosine receptor, a beta-adrenoceptor, a muscarinic receptor, a histamine receptor, an opiate receptor, a cannabinoid receptor, a chemokine receptor, an alpha-adrenoceptor, a GABA receptor, a prostanoid receptor, a 5-HT (serotonin) receptor, an excitatory aminoacid receptor (glutamate), a dopamine receptor, a protease-activating receptor, a neurokinin receptor, an angiotensin receptor, an oxytocin receptor, a leukotriene receptor, a nucleotide receptor (purines and pyrimidines), a calcium-sensing receptor, a thyroid-stimulating hormone receptor, a neuropeptid receptor, a vasopressin receptor, an olfactory receptor, a nucleobase receptor (adenosine), a lysophosphatidic acid receptor, a sphingolipid receptor, a tyramine receptor (trace amines), a free-fatty acid receptor and a cyclic nucleotide receptor;  
or wherein Lig is selected from

- a) xanthine like structures including XAC, theophylline, caffeine, theobromine, dyphilline, enprofylline; or fused biaryl structures including papaverine, dihydroquinolones, cilostamide, dipyridamole or vinpocetine; and analogues thereof;
- b) adenosine like structures including ADAC, NECA and analogues thereof;
- c) ethanolamine like structures including salmeterol, salbutamol, terbutaline, quinprenaline, labetalol, sotalol, bambuterol, fenoterol, reprotohol, tulobuterol, clenbuterol and analogues thereof;

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

- d) oxypropanolamine like structures including CGP12177, propranolol, practolol, acebutalol, betaxolol, ICI 118551, alprenolol, celpirolo (celectol), metoprolol (beta loc), CGP20712A, atenolol, bisoprolol, misaprolol, carvedilol, bucindolol, esmolol, nadolol, nebivolol, oxprenolol, xamoterol, pindolol, timolol and analogues thereof;
- e) xanthine like structures including XAC, theophylline, caffeine, theobromine, dyphilline, enprofylline, sildenafil, EHNA (erythro-9-(2-hydroxy-3-nonyl)adenine), zaprinast; or spiro bicyclic structures including bipyridines, amrinone; imidazolines, CI930; dihydropyridazinones, indolan, rolipram, SB207499; or fused biaryl structures including papaverine, dihydroquinilones, cilostamide, dipyridamole, vincocetine and analogues thereof.

53. (Withdrawn) Library as claimed in Claim 47 wherein  $J_{Lm}$  L  $J_{Tm}$  comprises a mono, di, tri, tetra, penta, or hexa amino, alkylthio, alkoxy, carboxylic acid, and combinations thereof including a mono, di or tri aminoalkylthio, amino alkoxy, alkoxy carboxylic acid or alkoxy amine, mono, di or tri amino menthane, amino ethane, thio ethane, ethane, amino acyl, polypeptide, or mono or polyether derivatives including diamine or dithio derivatives, mono or polyethylene glycol di or tri amine or thio;

or comprises a mono-, di-, tri- or tetra, penta or hexafunctional linear or branched or cyclic substituted or unsubstituted hydrocarbyl of formula —L.I-

$J [ A ] q_L R_L [ A' q_{L'} J' ]_p A'' q_{L''} J''$

wherein each of J to J'' is a linking site or functionality as hereinbefore defined independently selected from a single or double bond, methylene, alkyne, alkene, NR, O, CONR, NRCO, S, CO, NCO, CHHal and P wherein R is H or C<sub>1-8</sub> alkyl or cycloalkyl or forms part of a cyclic ring with

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

N, Hal is any halogen selected from chlorine, iodine, bromine; and is present in any rational location in a group A to A”;

each of A to A ” is a group selected from -O-, -C(=O)-, C<sub>1-12</sub> alkoxy, alkoyl, cycloalkyl, heterocyclic, alkyl, alkenyl, aryl, arylamide, arylamine, amino, thioalkyl, heteroaryl as hereinbefore defined and combinations thereof, optionally substituted by groups selected independently from C<sub>1-3</sub> alkyl and C<sub>1-5</sub> alkoxy;

each of q<sub>L</sub> to q<sub>L”</sub> are independently-selected from 0 or 1 or indicates an oligomeric repeat and is from 2 to 30, or indicates a polymeric repeat unit and is from 31 up to 300.

R<sub>L</sub> is a C, N or S atom or is a CR<sub>L</sub>, NR<sub>L</sub>, alkyl, cycloalkyl, heterocyclic, aryl heteroaryl, amine or thio moiety and provides for branching when p is 1 or 2; wherein R<sub>L</sub> is H or C<sub>1-3</sub> alkyl; and

p is as hereinbefore defined and is 0, 1 or 2.

54. (Withdrawn) Library as claimed in Claim 47 wherein J<sub>Lm</sub> L J<sub>Tm</sub> is of formula

J Aq<sub>L</sub> R<sub>L</sub> J”

wherein each of J and J” is amine or -O-, A is CH<sub>2</sub>CH<sub>2</sub>O, q<sub>L</sub> is 1-30 or 31 to 300 and R<sub>L</sub> is

CH<sub>2</sub>CH<sub>2</sub>

or of formula

J Aq<sub>L</sub> R<sub>L</sub>(A’J’) J”

wherein each of J, J’ and J” independently is amine, -O or a single bond, q<sub>L</sub> is 1, 2 or 3 -30 or 31 to 300 and A is CH<sub>2</sub>CH<sub>2</sub>O or HNCH<sub>2</sub>CO or q<sub>L</sub> is 1 and A is C(O) or (CH<sub>2</sub>)<sub>1-8</sub> or q<sub>L</sub> is 0, R<sub>L</sub> is CH or CH<sub>2</sub>CH, q<sub>L</sub> is 0 or q<sub>L</sub>’ is 1 and A’ is CH<sub>2</sub> and q<sub>L”</sub> is 0  
preferably

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

O(CH<sub>2</sub>CH<sub>2</sub>O)<sub>q1</sub>CH<sub>2</sub>CH<sub>2</sub>NH, O(CH<sub>2</sub>CH<sub>2</sub>O)<sub>q1</sub>CH<sub>2</sub>CH(CH<sub>2</sub>NH)NH,  
OCH(CH<sub>2</sub>NH)NH, -CH(CH<sub>2</sub>NH)NH, -(C(O) NH-, -(CH<sub>2</sub>)<sub>1-8</sub>- or (-HNCH<sub>2</sub>CO-)<sub>1-3</sub> (= -gly<sub>1-3</sub>-) -.

55. (Withdrawn-Previously Presented) Library as claimed in Claim 47 wherein each compound of formula I or I' comprises a moiety Lig and L as hereinbelow defined:

Wherein:

any optically active fluorescent ligand is present as a racemate or as one of its optically active isomers

Lig.a<sub>m</sub> is suitably of the formula, in either of the following forms given, including any of its possible linking configurations or sites:



Lig.a<sup>1</sup><sub>m</sub>

Wherein at least one or all of Ra<sup>1</sup> to Ra<sup>4</sup>, X<sup>1</sup> and X<sup>2</sup> comprise a linking site or functionality J as hereinbefore defined

X<sup>1</sup> and X<sup>2</sup> are each independently selected from H, O, OR.a, NR.a, NHR.a;

X<sup>1</sup> and X<sup>2</sup> are each preferably O;


each of R.a<sup>1</sup>, R.a<sup>2</sup>, R.a<sup>3</sup> and R.a<sup>4</sup> independently is selected from H or C<sub>1-4</sub> linear or branched alkyl optionally mono or multi hydroxy or halo substituted;

R.a<sup>4</sup> is selected from a heteroatom O, S or substituted or unsubstituted amine or saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)

may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo and cyano; including optionally substituted aryl, cycloalkyl, alkyl, ketone, (di)amine, (di)amide, alkoxy, cycloalkyl, carboxylic acid or optionally o-, m- or p- substituted phenyl wherein substituents include aryl, alkyl, cycloalkyl, heteroaryl or heteroalkyl, amine, amide, carboxyl, carbonyl or R.a<sup>4</sup> comprises cyclohexyl, cyclopentyl, ethoxy, (CH<sub>2</sub>)<sub>2</sub>PhPh, CH<sub>2</sub>Ph, CONH(CH<sub>2</sub>)<sub>n</sub>CONH, CH<sub>2</sub>CONH(CH<sub>2</sub>)<sub>2</sub>NH, CH<sub>2</sub>PhNHCOCH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>OCOCH<sub>2</sub>, succinimidyl ester, NHCOCH<sub>2</sub>, CH<sub>2</sub>(CH<sub>3</sub>)NCOCH<sub>2</sub>, H<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>NHCOCH<sub>2</sub>, H<sub>2</sub>N(CH<sub>2</sub>)<sub>8</sub>NHCOCH<sub>2</sub>, H<sub>2</sub>NNHCOCH<sub>2</sub>, CH<sub>2</sub>CONH(CH<sub>2</sub>)<sub>2</sub>NHCOCH<sub>2</sub>, HOPhCH<sub>2</sub>N(CH<sub>2</sub>CH<sub>3</sub>.HOAc)(CH<sub>2</sub>)<sub>2</sub>NHCOCH<sub>2</sub>, heterocyclic-(CH<sub>2</sub>)<sub>4</sub>CONH(CH<sub>2</sub>)<sub>2</sub>NHCOCH<sub>2</sub> or heterocyclic-NHCON(heterocyclic)COCH<sub>2</sub>;

or Lig.a is of the formula Lig.a<sup>2</sup>-



wherein at least one or all of Ra<sup>5</sup> to Ra<sup>6</sup>, or a cyclic C or heteroatom comprise a linking site or functionality J as hereinbefore defined, each of C.<sub>A1</sub> and C.<sub>A2</sub> is independently selected from C<sub>5-6</sub> aryl, heteroaryl, cycloalkyl and heterocyclic, more preferably from phenyl, or aryl containing 1 or 2 ring heteroatoms, or heterocyclic containing 1 ring heteroatom and/or 1 ring -C=C- group; Each of up to seven R.a<sup>5</sup> is a substituent of a ring carbon or a ring heteroatom and:

is independently selected from H, halo, hydroxy, thiol, amine, COOH, hydrazine, cyano, saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, and wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo =O or cyano; OCH<sub>3</sub>, CH<sub>2</sub>Ph(OCH<sub>3</sub>)<sub>2</sub>, O(CH<sub>2</sub>)<sub>2</sub>CON(CH<sub>3</sub>).c.hex, N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, c.hex, COOCH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>;

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)


or      any two or more of R.a<sup>5</sup> form a one, two or three ring fused cyclic structure, a fused 3 ring aryl, 5-heterocyclic or 6-heterocyclic structure having 4 ring atoms common with the fused bicyclic Lig.a<sup>2</sup> structure;

and     R.a<sup>6</sup> is a moiety as defined for R.a<sup>5</sup> above;

and L.a      is as hereinbefore defined for L or J<sub>L</sub> L J<sub>T</sub> or L.I or subformulae as hereinbefore defined, or is amino acid or amide including a peptide or polypeptide gly or gly<sub>3</sub>, alkyl of formula -(CH<sub>2</sub>)<sub>n</sub> where n is 3 to 8, optionally including one or more heteroatoms or unsaturated groups, including -O- or -S- or -CH=CH-;

Lig.b    is suitably of the formula Lig.b including any of its possible linking configurations or sites:

Lig.b



wherein      at least one or all of Rb<sup>1</sup> to Rb<sup>5</sup> or Xb<sup>1</sup> to Xb<sup>3</sup> comprise a linking site or functionality J as hereinbefore defined

ring substituents X.b<sup>1</sup> and X.b<sup>2</sup> are independently selected from hydrocarbon including alkyl or SR<sub>X</sub>, NR<sub>X,2</sub> and OR<sub>X</sub> wherein (each) R<sub>X</sub> is selected from H, C<sub>1-5</sub>alkyl, alkenyl; ring heteroatom X.b<sup>3</sup> is selected from -S-, -O- and -CH<sub>2</sub>-;

Rb<sup>1</sup>    is selected from saturated or unsaturated, substituted or unsubstituted C<sub>1-4</sub> aliphatic, or C<sub>1-3</sub> alicyclic optionally including one or more heteroatoms N, O, S, P, wherein substituent(s) are selected from one or more cycloalkyl, heterocyclic, hydroxy, oxo, halo, amine; or R.b<sup>1</sup> comprises a carbonyl substituted by H, alkyl or a linear or cyclic primary, secondary or tertiary amine, substituted C<sub>1-3</sub> alkyl, cycloalkyl or amide, cyclopropyl, or CONHC<sub>1-3</sub>alkyl including CONHET or CH<sub>2</sub>OH

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

and each of R.b<sup>2</sup> and R.b<sup>3</sup> is selected from H, halo, hydroxy, thiol, amine, COOH, CHO, hydrazine, cyano or saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo or cyano, preferably from H, halo or hydroxy;


Rb<sup>4</sup> is H;

Rb<sup>5</sup> is H or alkyl

L.b comprises a linking site or functionality J as hereinbefore defined; and is as hereinbefore defined for L or its subformulae, more preferably is saturated and unsaturated substituted or unsubstituted C<sub>1-12</sub> aliphatic or C<sub>1-24</sub> aromatic as defined for L optionally including one or more heteroatoms O, S or N, cyclic or heterocyclic groups, or is of formula L.I or its subformulae as hereinbefore defined, or is (CH<sub>2</sub>)<sub>m</sub> wherein m is 2 to 12, or is (Ph-CH<sub>2</sub>CONH)<sub>2</sub> (CH<sub>2</sub>)<sub>2</sub>;

Lig.c is of the formula Lig.c including any of its possible linking configurations or sites:

Lig.c      HO-C(R.c<sup>1</sup>)-NH-R.c<sup>2</sup>




where at least one or all of Rc<sup>1</sup> to Rc<sup>2</sup> or OH, or a chain C or N comprise a linking site or functionality J as hereinbefore defined

\* indicates an optically active centre and


wherein R.c<sup>1</sup> is C<sub>6-14</sub> aryl optionally including one or more heteroatoms selected from H, O, optionally substituted by OH, Hal, NH<sub>2</sub>, NHC<sub>1-3</sub>alkyl, sulphonamide, oxoamine or (-CONH<sub>2</sub>), or is mono, di or tri substituted phenyl or quinoline wherein substituents include OH, Cl or NH<sub>2</sub>, or is m-CH<sub>2</sub>OH, p-OH phenyl,

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)

m-,p-dihydroxy phenol or m-,m-dihydroxyphenol, m-,m-diCl, p-NH<sub>2</sub> phenol, p-OH, m-CONH<sub>2</sub> phenol or 5-OH, 8-quinoline,



R.c<sup>2</sup> is selected from saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any optionally substituted C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo or cyano and combinations thereof; or R.c<sup>2</sup> is selected from C<sub>1-6</sub> branched or straight chain aliphatic, C<sub>6-10</sub> araliphatic optionally substituted by OH and optionally including heteroatoms selected from N,O, optionally including an ether O, and is selected from -(CH<sub>2</sub>)<sub>6</sub>OCH((CH<sub>2</sub>)<sub>3</sub>Ph), CHCH<sub>3</sub>(CH<sub>2</sub>)<sub>2</sub>Ph, CHCH<sub>3</sub>CH<sub>2</sub>PhOH, C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>Ph or from the structures:




L.c is present as R.c<sup>2</sup> or comprises a linking site or functionality J as hereinbefore defined, and is as hereinbefore defined for L, formula L.I or its subformulae as hereinbefore defined, or is selected from C<sub>1-12</sub> alkyl, amide;

Lig.d is of the formula Lig.d including any of its possible linking configurations or sites:

Lig.d            R.d<sup>1</sup> OCH<sub>2</sub>C\*HOHCH<sub>2</sub>NH-R.d<sup>2</sup>





SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)



where at least one or all of Rd<sup>1</sup> to Rd<sup>2</sup> or OH, a chain C or N comprise a linking site or functionality J as hereinbefore defined


\* indicates an optically active centre

wherein R.d<sup>1</sup> is saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo or cyano; or R.d<sup>1</sup> is substituted or unsubstituted C<sub>1-24</sub> aralkyl or heteroaralkyl, including single ring and fused ring systems with (hetero)aryl or cycloalkyl rings, wherein optional substituents include C<sub>1-6</sub> alkyl, alkoxy, ether, carbonyl, alkenyl, amine, amide each optionally carbonyl, amide, halo or OH substituted, or halo or OH, amine, amide, carbonyl, ketone, ether substituted phenyl or naphthyl, mono-, di-, tri- or tetra substituted mono or polycyclic fused aryl or cycloaryl or heterocycloaryl including phenyl, carbazole or structures shown below or spiro ring systems, mono-, di-, tri- or tetra alkoxyalkyl, alkoxyalkoxyalkyl or CF<sub>3</sub> substituted phenyl or unsubstituted or monosubstituted naphthalene or 5,6 ring systems:



SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)

R.d<sup>2</sup> is substituted or unsubstituted amine, saturated or unsaturated, substituted or unsubstituted C<sub>1-12</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo or cyano, more preferably amine, C<sub>1-6</sub> branched or straight chain alkyl optionally including ether O, and optionally substituted by C<sub>6-10</sub> aryl, or of the formula:



L.d may be present as R.d<sup>2</sup> or may comprise a linking site or functionality J as hereinbefore defined and is as hereinbefore defined for L and its subformulae , formula L.I and its subformulae as hereinbefore defined, or is as hereinbefore defined for L.a;


Lig.c comprises a cell permeant moiety or is associated with a cell permeant L or Fl moiety or is of the formula , in either of the following forms given including any of its possible linking configurations or sites:

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
 U.S. Application No. 10/551,475 (Q111431)

Lig.e<sup>1</sup>



wherein at least one or all of Re<sup>1</sup> to Re<sup>4</sup>, X and a ring C or N comprise a linking site or functionality J as hereinbefore defined  
 h is selected from



each optionally substituted by R.c<sup>3</sup> – R.c<sup>4</sup> wherein R.c<sup>1</sup> – R.c<sup>4</sup> are as R.a<sup>1</sup> – R.a<sup>4</sup> defined above or in which R.c<sup>3</sup> is C<sub>5,9</sub> linear or branched alkyl, optionally mono or multi hydroxy or halo substituted or is aryl optionally substituted by alkoxy or sulfonyl,

ortho-OEt, meta-SO<sub>2</sub>N                  NCH<sub>3</sub>

each X is independently selected from H, O, -OR.c<sup>2</sup>, N, HN, NR.c<sup>5</sup>, HR.c<sup>6</sup>, and aryl optionally substituted by ether; or X is aryl optionally alkyl or alkoxy substituted or is Ph-ortho-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>;


**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

and where R.e<sup>5</sup> is as defined above for R.e<sup>1</sup> above or forms a fused cyclic ring together with the adjacent ring N atom, or 1 or 2 fused 5 membered cyclic rings;

and R.e<sup>6</sup> is as defined above for R.e<sup>1</sup> above or is selected from optionally substituted phenyl wherein optional substituents include ether, o-ethoxy or o-propoxy, alkyl or OH, sulphonyl or carbonyl substituted by heterocyclic, or cyclic C<sub>5-8</sub> alkyl, piperazinyl or sulphonyl;

or Lig.c is of the formula Lig.c<sup>2</sup>

Lig.c<sup>2</sup>



wherein at least one or all free ring atom or their substituents comprise a linking site or functionality J as hereinbefore defined

each spiro ring optionally comprises zero or one or more heteroatoms h


or (h)  comprises zero or 1 N

heteroatom and  5,6(h) comprises zero, 1 or 2 N heteroatoms and is unsaturated or comprises one or two -C=C- or -C=N- groups;

and wherein each ring is optionally substituted by one or more oxo, CO, COOH, C<sub>1-6</sub> alkyl or linear or cyclic alkoxy optionally substituted by one or more oxo, CO, COOH, CN, or C<sub>1-6</sub> alicyclic or amine groups, amine or one or more spiro or fused heterocycles;

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)

or Lig.e is of the formula Lig.e<sup>3</sup>



wherein      at least one or all of R.e<sup>11</sup> to R.e<sup>12</sup>, or a ring C or heteroatom or ring substituent comprise a linking site or functionality J as hereinbefore defined

each of C.E1 and C.E2 is independently selected from C<sub>5-6</sub> aryl, heteroaryl, cyloalkyl and heterocyclic, including phenyl, or aryl containing 1 or 2 ring heteroatoms, or heterocyclic containing 1 ring heteroatom and/or 1 ring -C=C- group;

each of up to seven R.e<sup>11</sup> is a substituent of a ring carbon or a ring heteroatom and:

is independently selected from saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, and wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo =O, or cyano, OCH<sub>3</sub>, CH<sub>2</sub>Ph(OCH<sub>3</sub>)<sub>2</sub>, O(CH<sub>2</sub>)<sub>3</sub>CON(CH<sub>3</sub>)<sub>2</sub>c.hex, N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, c.hex, COOCH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>;

or any two or more of R.e<sup>11</sup> form a one, two or three ring fused cyclic structure, a fused 3 ring aryl, 5-heterocyclic or 6-heterocyclic structure having 4 ring atoms common with the fused bicyclic Lig.e<sup>3</sup> structure;

and R.e<sup>12</sup> is a moiety as defined for R.e<sup>11</sup> above;

L.e      comprises a linking site or functionality J as hereinbefore defined and is suitably as hereinbefore defined for L.a.

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

57. (Withdrawn-Previously Presented) Library as claimed in Claim 47 wherein  $\text{Fl}$  is of formula  $\text{J}_\text{T} - \text{t} - \text{Fl}$  and comprises a BODIPY™ structure characterised by a dipyrrometheneboron difluoride core, optionally modified by one or two fused rings, optionally substituted by one or several substituents selected from alkyl, alkoxy, aryl or heterocyclic, wherein one substituent  $-\text{t}-$  is adapted for linking as hereinbefore defined to a ligand precursor as hereinbefore defined, wherein the substituent  $-\text{t}-$  comprises a proximal unsaturated or aryl moiety, comprising a medial short, medium or long chain alkynyl or cycloalkyl moiety and comprising a moiety derived from linking via a reactive group as hereinbefore defined or selected from carboxyl, sulphonate or as a heteroatom O or S or methylene derived from linking at an alkylhalide including methylbromide, haloacetamide or sulphonate ester electrophilic group.

58. (Cancelled).

59. (Withdrawn-Previously Presented) Process for the preparation of a library as claimed in Claim 47 which is a combinatorial process; and comprises the reaction of one or more ligand precursors of formula IV and/or IV'

IV       $(\text{LigJ}_\text{L})_\text{m} - \text{L} - \text{Y}_{\text{Lm}}$

IV'      Lig  $\text{Y}_{\text{Ligm}}$

comprising one or more or different reactive groups  $\text{Y}_\text{L}$  or  $\text{Y}_{\text{Lig}}$  forming a linking functionality  $\text{J}$ ,  $\text{J}_\text{L}$  or  $\text{J}_\text{T}$  as hereinbefore defined

with one or more of a plurality of analytical tagging substrates of formula V and/or V'

V       $\text{Y}_{\text{Tm}} \text{ Tag}$

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

V'       $Y_{Tm} L (J_T \text{Tag})_m$

comprising one or more or different reactive groups  $Y_T$  forming a linking functionality  $J$  or  $J_T$  as hereinbefore defined

and optionally one or more linking species VI or VI' or VI''

VI       $Y_{Lm} L Y_{Lm}$

wherein Lig, J, L,  $J_T$  and Tag and each m is independently as hereinbefore defined

wherein the or each compound of formula IV or IV' is capable of reaction with the or each compound of formula V or V', optionally via the or each species VI or VI' or VI'' to form a plurality of compounds of formula I as hereinbefore defined;

wherein linking is at same or different reactive sites in different compounds as hereinbefore defined.

60. (Withdrawn-Previously Presented) Process for the preparation of a compound of formula I as hereinbelow defined in Claim 64 comprising the reaction of a compound of formula IV or IV' and a compound of formula V or V' and optionally additionally VI, as hereinbefore defined in claim 59.


61-62. (Cancelled).

63. (Withdrawn-Previously Presented) Process as claimed in Claim 59 which comprises additionally determining pharmacology for a plurality of or all compounds in the library in order to enable selecting a compound exhibiting desired pharmacology, whereby the process comprises preparing a preliminary library of compounds, conducting screens to assess

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

binding or inhibition, selecting a compound identified in the screen as having beneficial properties, and modifying or functionalising by nature of moieties or linking location of linking on the basis of the indications from the screen to prepare an optimised library, wherein the molecular pharmacology and photochemistry from the screen feedback into the design of the library.

64. (Previously Presented) A compound of formula I



or salt thereof wherein an optically active ligand is present as a racemate or as one of its optically active isomers

comprising ligand moiety Lig linked to tag moiety Tag via linker moiety L at linking site or linking functionality J<sub>T</sub> and J<sub>L</sub>

wherein Lig is a ligand selected from a non-peptide GPCR ligand agonist and a non-peptide GPCR ligand antagonist, wherein the Lig comprises pharmacological activity as an agonist or antagonist or GPCR receptor binding and activation or inhibition

L is selected from amine, amide, saturated or unsaturated, substituted or unsubstituted C<sub>1-600</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, wherein optional substituents are selected from any C<sub>1-20</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano and carbonyl and combinations thereof, and L is monomeric,

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

oligomeric having oligomeric repeat of 2 to 30 or polymeric having polymeric repeat in excess of 30 up to 300;

m are each independently selected from a whole number integer from 1 to 3;

p is 0 to 3

wherein -Tag is a fluorophore entity -Fl, whereby the compound is of formula I'

(LigJ<sub>L</sub>)<sub>m</sub> L (J<sub>T</sub> Fl)<sub>m</sub> (J<sub>T</sub> L (J<sub>L</sub> Lig)<sub>m</sub>)<sub>p</sub>

wherein Fl is selected from a red, near ir or blue dye and

the compound of formula I or I' retains pharmacological activity as a fluorescent GPCR ligand agonist or fluorescent GPCR ligand antagonist for GPCR receptor binding and activation or inhibition..

65. (Previously Presented) A compound of formula I as defined in Claim 64 which is a compound of formula II or III

II (LigJ<sub>L</sub>)<sub>m</sub> L J<sub>T</sub> TagJ<sub>T</sub> L (J<sub>L</sub> Lig)<sub>m</sub> where each m is as hereinbefore defined and is preferably 1 or 2, more preferably 1

III (LigJ<sub>L</sub>)<sub>m</sub> L (J<sub>T</sub> Tag)<sub>m</sub> wherein each m is as hereinbefore defined and is preferably 1 and/or 2, more preferably

Lig J<sub>L</sub> - L - J<sub>L</sub> Tag and/or

Lig J<sub>L</sub> - L - J<sub>T</sub> Tag and/or Lig J<sub>L</sub> - L - J<sub>T</sub> Tag

\J<sub>L</sub> Lig

\J<sub>T</sub> Tag

and wherein any optically active fluorescent ligand is present as a racemate or as one of its optically active isomers.

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

66. (Previously Presented) A compound according to Claim 64, wherein Fl is of formula J<sub>T</sub> – t – Fl and comprises a BODIPY™ structure 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-3-yl characterised by a dipyrrometheneboron difluoride core, optionally modified by one or two fused rings, optionally substituted by one or several substituents selected from alkyl, alkoxy, aryl or heterocyclic, wherein one substituent –t- is adapted for linking as hereinbefore defined to a ligand precursor as hereinbefore defined, wherein the substituent –t- comprises a proximal unsaturated or aryl moiety, comprising a medial short, medium or long chain alkynyl or cycloalkyl moiety and comprising a moiety derived from linking via a reactive group as hereinbefore defined or selected from carboxyl, sulphonate or as a heteroatom O or S or methylene derived from linking at an alkylhalide including methylbromide, haloacetamide or sulphonate ester electrophilic group.

67. (Withdrawn-Previously Presented) A compound of the formula I or I' as hereinbefore defined in Claim 64 selected from formulae Lig.<sub>a</sub><sub>m</sub> L.<sub>a</sub>Fl.<sub>a</sub><sub>n</sub> to Lig.<sub>c</sub><sub>m</sub> L.<sub>c</sub>Fl.<sub>c</sub><sub>n</sub>, wherein:

Lig.<sub>a</sub><sub>m</sub> is suitably of the formula, in either of the following forms given, including any of its possible linking configurations or sites:



**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

Lig.a<sup>1\_m</sup>

Wherein at least one or all of Ra<sup>1</sup> to Ra<sup>4</sup>, X<sup>1</sup> and X<sup>2</sup> comprise a linking site or functionality J as hereinbefore defined


X<sup>1</sup> and X<sup>2</sup> are each independently selected from H, O, OR.a, NR.a, NHR.a;

X<sup>1</sup> and X<sup>2</sup> are each preferably O;

each of Ra<sup>1</sup>, Ra<sup>2</sup>, Ra<sup>3</sup> and Ra<sup>4</sup> independently is selected from H or C<sub>1-4</sub> linear or branched alkyl optionally mono or multi hydroxy or halo substituted;

R.a<sup>4</sup> is selected from a heteroatom O, S or substituted or unsubstituted amine or saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo and cyano; including optionally substituted aryl, cycloalkyl, alkyl, ketone, (di)amine, (di)amide, alkoxy, cycloalkyl, carboxylic acid or optionally o-, m- or p- substituted phenyl wherein substituents include aryl, alkyl, cycloalkyl, heteroaryl or heteroalkyl, amine, amide, carboxyl, carbonyl or R.a<sup>4</sup> comprises cyclohexyl, cyclopentyl, ethoxy, (CH<sub>2</sub>)<sub>2</sub>PhPh, CH<sub>2</sub>Ph, CONH(CH<sub>2</sub>)<sub>n</sub>CONH, CH<sub>2</sub>CONH(CH<sub>2</sub>)<sub>2</sub>NH, CH<sub>2</sub>PhNHCOCH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>OCOCH<sub>2</sub>, succinimidyl ester, NHCOCH<sub>2</sub>, CH<sub>2</sub>(CH<sub>3</sub>)NCOCH<sub>2</sub>, H<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>NHCOCH<sub>2</sub>, H<sub>2</sub>N(CH<sub>2</sub>)<sub>8</sub>NHCOCH<sub>2</sub>, H<sub>2</sub>NNHCOCH<sub>2</sub>, CH<sub>2</sub>CONH(CH<sub>2</sub>)<sub>2</sub>NHCOCH<sub>2</sub>, HOPhCH<sub>2</sub>N(CH<sub>2</sub>CH<sub>3</sub>.HOAc)(CH<sub>2</sub>)<sub>2</sub>NHCOCH<sub>2</sub>, heterocyclic-(CH<sub>2</sub>)<sub>4</sub>CONH(CH<sub>2</sub>)<sub>2</sub>NHCOCH<sub>2</sub> or heterocyclic-NHCON(heterocyclic)COCH<sub>2</sub>;

or Lig.a is of the formula Lig.a<sup>2</sup>-



**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

wherein at least one or all of Ra<sup>5</sup> to Ra<sup>6</sup>, or a cyclic C or heteroatom comprise a linking site or functionality J as hereinbefore defined, each of C.<sub>A1</sub> and C.<sub>A2</sub> is independently selected from C<sub>5-6</sub> aryl, heteroaryl, cycloalkyl and heterocyclic, more preferably from phenyl, or aryl containing 1 or 2 ring heteroatoms, or heterocyclic containing 1 ring heteroatom and/or 1 ring -C=C- group; Each of up to seven R.a<sup>5</sup> is a substituent of a ring carbon or a ring heteroatom and:

is independently selected from H, halo, hydroxy, thiol, amine, COOH, hydrazine, cyano, saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, and wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo =O or cyano; OCH<sub>3</sub>, CH<sub>2</sub>Ph(OCH<sub>3</sub>)<sub>2</sub>, O(CH<sub>2</sub>)<sub>3</sub>CON(CH<sub>3</sub>)c.hex, N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, c.hex, COOCH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>;

or      any two or more of R.a<sup>5</sup> form a one, two or three ring fused cyclic structure, a fused 3 ring aryl, 5-heterocyclic or 6-heterocyclic structure having 4 ring atoms common with the fused bicyclic Lig.a<sup>2</sup> structure;


and     R.a<sup>6</sup> is a moiety as defined for R.a<sup>5</sup> above;

and L.a      is as hereinbefore defined for L or J<sub>L</sub> L J<sub>T</sub> or L.I or subformulae as hereinbefore defined, or is amino acid or amide including a peptide or polypeptide gly or gly<sub>3</sub>, alkyl of formula -(CH<sub>2</sub>)<sub>n</sub> where n is 3 to 8, optionally including one or more heteroatoms or unsaturated groups, including -O- or -S- or -CH=CH-:

Lig.b    is suitably of the formula Lig.b including any of its possible linking configurations or sites:

Lig.b

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)



wherein at least one or all of  $Rb^1$  to  $Rb^5$  or  $Xb^1$  to  $Xb^3$  comprise a linking site or functionality J as hereinbefore defined

ring substituents  $X.b^1$  and  $X.b^2$  are independently selected from hydrocarbon including alkyl or  $SR_X$ ,  $NR_{X,2}$  and  $OR_X$  wherein (each)  $R_X$  is selected from H,  $C_{1-5}$ alkyl, alkenyl; ring heteroatom  $X.b^3$  is selected from  $-S-$ ,  $-O-$  and  $-CH_2-$ ;

$Rb^1$  is selected from saturated or unsaturated, substituted or unsubstituted  $C_{1-4}$  aliphatic, or  $C_{1-3}$  alicyclic optionally including one or more heteroatoms N, O, S, P, wherein substituent(s) are selected from one or more cycloalkyl, heterocyclic, hydroxy, oxo, halo, amine; or  $R.b^1$  comprises a carbonyl substituted by H, alkyl or a linear or cyclic primary, secondary or tertiary amine, substituted  $C_{1-3}$  alkyl, cycloalkyl or amide, cyclopropyl, or  $CONHC_{1-3}$ alkyl including  $CONHEt$  or  $CH_2OH$

and each of  $R.b^2$  and  $R.b^3$  is selected from H, halo, hydroxy, thiol, amine, COOH, CHO, hydrazine, cyano or saturated or unsaturated, substituted or unsubstituted  $C_{1-20}$  branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any  $C_{1-12}$  aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo or cyano, preferably from H, halo or hydroxy;

$Rb^4$  is H;

$Rb^5$  is H or alkyl


$L.b$  comprises a linking site or functionality J as hereinbefore defined; and is as hereinbefore defined for L or its subformulae, more preferably is saturated and unsaturated substituted or unsubstituted  $C_{1-12}$  aliphatic or  $C_{1-24}$  aromatic as defined for L optionally including one or more heteroatoms O, S or N, cyclic or

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)

heterocyclic groups, or is of formula L.I or its subformulae as hereinbefore defined, or is  $(\text{CH}_2)_m$  wherein m is 2 to 12, or is  $(\text{Ph}-\text{CH}_2\text{CONH})_2(\text{CH}_2)_2$ ;

Lig.c is of the formula Lig.c including any of its possible linking configurations or sites:


Lig.c  $\text{HO}^*(\text{R.c}^1)\text{CH}_2\text{NH-R.c}^2$



where at least one or all of R<sup>c1</sup> to R<sup>c2</sup> or OH, or a chain C or N comprise a linking site or functionality J as hereinbefore defined

\* indicates an optically active centre and


wherein R.c<sup>1</sup> is C<sub>6-14</sub> aryl optionally including one or more heteroatoms selected from H, O, optionally substituted by OH, Hal, NH<sub>2</sub>, NHC<sub>1-3</sub>alkyl, sulphonamide, oxoamine or (-CONH<sub>2</sub>), or is mono, di or tri substituted phenyl or quinoline wherein substituents include OH, Cl or NH<sub>2</sub>, or is m-CH<sub>2</sub>OH, p-OH phenyl, m-,p-dihydroxy phenol or m-,m-dihydroxyphenol, m-,m-diCl, p-NH<sub>2</sub> phenol, p-OH, m-CONH<sub>2</sub> phenol or 5-OH, 8-quinoline,



R.c<sup>2</sup> is selected from saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any optionally substituted C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo or cyano and combinations thereof; or R.c<sup>2</sup> is selected from C<sub>1-6</sub> branched or straight chain aliphatic, C<sub>6-10</sub> araliphatic optionally substituted by OH and

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)


optionally including heteroatoms selected from N, O, optionally including an ether O, and is selected from  $-(CH_2)_6OCH((CH_2)_3Ph)$ ,  $CHCH_3(CH_2)_2Ph$ ,  $CHCH_3CH_2PhOH$ ,  $C(CH_3)_2CH_2Ph$  or from the structures:



L.c is present as R.c<sup>2</sup> or comprises a linking site or functionality J as hereinbefore defined, and is as hereinbefore defined for L, formula L.I or its subformulae as hereinbefore defined, or is selected from C<sub>1-12</sub> alkyl, amide;

Lig.d is of the formula Lig.d including any of its possible linking configurations or sites:

Lig.d R.d<sup>1</sup> OCH<sub>2</sub>C\*HOHCH<sub>2</sub>NH-R.d<sup>2</sup>




where at least one or all of Rd<sup>1</sup> to Rd<sup>2</sup> or OH, a chain C or N comprise a linking site or functionality J as hereinbefore defined

\* indicates an optically active centre


wherein R.d<sup>1</sup> is saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo or cyano; or R.d<sup>1</sup> is substituted or unsubstituted C<sub>1-24</sub> aralkyl or heteroaralkyl, including single ring and fused ring systems with (hetero)aryl or cycloalkyl rings, wherein optional substituents include C<sub>1-6</sub> alkyl, alkoxy, ether, carbonyl, alkenyl, amine, amide each optionally carbonyl, amide, halo or OH substituted, or halo or OH, amine, amide, carbonyl, ketone, ether substituted phenyl or naphthyl, mono-, di-, tri- or

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)

tetra substituted mono or polycyclic fused aryl or cycloaryl or heterocycloaryl including phenyl, carbazole or structures shown below or spiro ring systems, mono-, di-, tri- or tetra alkoxyalkyl, alkoxyalkoxyalkyl or CF<sub>3</sub> substituted phenyl or unsubstituted or monosubstituted naphthalene or 5,6 ring systems:



R.d<sup>2</sup> is substituted or unsubstituted amine, saturated or unsaturated, substituted or unsubstituted C<sub>1-12</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo or cyano, more preferably amine, C<sub>1-6</sub> branched or straight chain alkyl optionally including ether O, and optionally substituted by C<sub>6-10</sub> aryl, or of the formula:



SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)

L.d may be present as R.d<sup>2</sup> or may comprise a linking site or functionality J as hereinbefore defined and is as hereinbefore defined for L and its subformulae , formula L.I and its subformulae as hereinbefore defined, or is as hereinbefore defined for L.a;



Lig.e comprises a cell permeant moiety or is associated with a cell permeant L or Fl moiety or is of the formula , in either of the following forms given including any of its possible linking configurations or sites:

Lig.e<sup>1</sup>



wherin at least one or all of Re<sup>1</sup> to Re<sup>4</sup>, X and a ring C or N comprise a linking site or functionality J as hereinbefore defined

h is selected from



each optionally substituted by R.e<sup>3</sup> – R.e<sup>4</sup> wherein R.e<sup>1</sup> – R.e<sup>4</sup> are as R.a<sup>1</sup> – R.a<sup>4</sup> defined above or in which R.e<sup>3</sup> is C<sub>5,9</sub> linear or branched alkyl, optionally mono or

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

multi hydroxy or halo substituted or is aryl optionally substituted by alkoxy or sulfonyl,

ortho-OEt, meta-SO<sub>2</sub>N                    NCH<sub>3</sub>


each X is independently selected from H, O, -OR.<sup>e2</sup>, N, HN, NR.<sup>e5</sup>, HR.<sup>e6</sup>, and aryl optionally substituted by ether; or X is aryl optionally alkyl or alkoxy substituted or is Ph-ortho-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>;

and where R.<sup>e5</sup> is as defined above for R.<sup>e1</sup> above or forms a fused cyclic ring together with the adjacent ring N atom, or 1 or 2 fused 5 membered cyclic rings;

and R.<sup>e6</sup> is as defined above for R.<sup>e1</sup> above or is selected from optionally substituted phenyl wherein optional substituents include ether, o-ethoxy or o-propoxy, alkyl or OH, sulphonyl or carbonyl substituted by heterocyclic, or cyclic C<sub>5-8</sub> alkyl, piperazinyl or sulphonyl;

or Lig.e is of the formula Lig.e<sup>2</sup>

Lig.e<sup>2</sup>



SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)

wherein at least one or all free ring atom or their substituents comprise a linking site or functionality J as hereinbefore defined

each spiro ring optionally comprises zero or one or more heteroatoms h


or

(h)  comprises zero or 1 N

heteroatom and  5,6(h) comprises zero, 1 or 2 N heteroatoms and is unsaturated or comprises one or two -C=C- or -C=N- groups;

and wherein each ring is optionally substituted by one or more oxo, CO, COOH, C<sub>1-6</sub> alkyl or linear or cyclic alkoxy optionally substituted by one or more oxo, CO, COOH, CN, or C<sub>1-6</sub> alicyclic or amine groups, amine or one or more spiro or fused heterocycles;

or Lig.c is of the formula Lig.c<sup>3</sup>



wherein at least one or all of R.c<sup>11</sup> to R.c<sup>12</sup>, or a ring C or heteroatom or ring substituent comprise a linking site or functionality J as hereinbefore defined

each of C.E1 and C.E2 is independently selected from C<sub>5-6</sub> aryl, heteroaryl, cyloalkyl and heterocyclic, including phenyl, or aryl containing 1 or 2 ring heteroatoms, or heterocyclic containing 1 ring heteroatom and/or 1 ring -C=C- group;

each of up to seven R.c<sup>11</sup> is a substituent of a ring carbon or a ring heteroatom and:

is independently selected from saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, and wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo =O, or cyano, OCH<sub>3</sub>,

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**


CH<sub>2</sub>Ph(OCH<sub>3</sub>)<sub>2</sub>, O(CH<sub>2</sub>)<sub>3</sub>CON(CH<sub>3</sub>)c.hex, N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, c.hex, COOCH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>;

or any two or more of R.e<sup>11</sup> form a one, two or three ring fused cyclic structure, a fused 3 ring aryl, 5-heterocyclic or 6-heterocyclic structure having 4 ring atoms common with the fused bicyclic Lig.c<sup>3</sup> structure;

and R.e<sup>12</sup> is a moiety as defined for R.e<sup>11</sup> above;

L.c comprises a linking site or functionality J as hereinbefore defined and is suitably as hereinbefore defined for L.a.

68. (Previously Presented) A compound of the formula I



or salt thereof and salts thereof wherein an optically active ligand is present as a racemate or as one of its optically active isomers

comprising ligand moiety Lig linked to tag moiety Tag via linker moiety L at linking site or linking functionality J<sub>T</sub> and J<sub>L</sub>

wherein Lig is a ligand selected from a non-peptide GPCR ligand agonist and a non-peptide GPCR ligand antagonist, wherein the Lig comprises pharmacological activity as an agonist or antagonist for GPCR receptor binding and activation or inhibition

L is selected from amine, amide, saturated or unsaturated, substituted or unsubstituted C<sub>1-600</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, wherein optional substituents are selected from any C<sub>1-20</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano and carbonyl and combinations thereof, and L may be monomeric, oligomeric having oligomeric repeat of 2 to 30 or polymeric having polymeric repeat in excess of 30 up to 300;

m are each independently selected from a whole number integer from 1 to 3;

p is 0 to 3

wherein -Tag is a fluorophore entity -Fl, whereby the compound is of formula I'

$(\text{LigJ}_L)_m \text{ L } (\text{J}_T \text{ Fl})_m (\text{J}_T \text{ L } (\text{J}_L \text{ Lig})_m)_p$

wherein Fl is selected from the class of dyes including TEXAS RED<sup>TM</sup> sulforhodamine 101 acid chloride, coumarin and derivatives, CASCADE BLUE<sup>TM</sup> pyrenyloxytrisulfonic acid, EVOBLUE<sup>TM</sup> oxazine based dyes and fluorescent derivatives thereof, pyrenes and pyridyloxazole derivatives, the cyanine dyes, the dyomics (DY dyes and ATTO dyes) and fluorescent derivatives thereof, the Alexafluor dyes and derivatives, BDI dyes including the commercially available Bodipy<sup>TM</sup> 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-3-yl dyes, pyrenes, anthracenes, acridines, fluorescent phycobiliproteins and their conjugates and fluoresceinated microbeads, and TEXAS RED<sup>TM</sup> sulforhodamine 101 acid chloride derivatives, coupled to amine groups using the isocyanate, succinimidyl ester or dichlorotriazinyl-reactive groups and the compound of formula I or I' retains pharmacological activity as a fluorescent GPCR ligand agonist or fluorescent GPCR ligand antagonist for GPCR receptor binding and activation or inhibition.

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

69. (Withdrawn-Previously Presented) A kit comprising a Compound of formula I or I' as hereinbefore defined in Claim 47 associated with information relating to its pharmacological properties in the form of Spectral Properties given as Excitation Max and Emission Max, Fluorescence Lifetime and Emission quantum yield and Pharmacology defined in terms of cells expressing a GPCR receptor as hereinbefore defined and given as the Inhibition or Antagonism of receptor binding or of receptor functionality together with a value for the Inhibition ( $pK_B$ ) or Antagonism ( $pK_i$ ) binding constants, and optionally together with fluorescent images of the pharmacological binding in single living cells illustrating the defined inhibition or antagonism, preferably the pharmacological properties are given as EC<sub>50</sub> values for agonist stimulated – or pK<sub>i</sub> values for antagonism of agonist stimulated second messenger generation.

70. (Withdrawn-Previously Presented) Compound of formula IV or IV' or library thereof as hereinbefore defined in Claim 59.

71. (Withdrawn-Previously Presented) Fluorophore linker of formula V' or library thereof as hereinbefore defined in Claim 59.

72. (Withdrawn-Previously Presented) Kit comprising ligand precursors, linker precursors and tag precursors of formulae IV, IV', V, V' and/or VI as hereinbefore defined in Claim 59 for preparing a library of compounds of formula I ( $\text{Lig J}_L)_m \text{ L}(\text{J}_T\text{Tag})_m (\text{J}_T \text{ L}(\text{J}_L\text{Lig})_m)_p$  and salts thereof wherein any optically active fluorescent ligand is present as a racemate or as one of its optically active isomers

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

comprising one or a plurality of same or different ligand moieties Lig each linked to one or a plurality of same or different tag moieties Tag via same or different linker moieties L and same or different linking site or linking functionality J<sub>T</sub> and J<sub>L</sub>

wherein Lig is a ligand selected from a non-peptide GPCR ligand agonist and a non-peptide GPCR ligand antagonist, wherein the Lig comprises pharmacological activity as an agonist or antagonist or GPCR receptor binding and activation or inhibition


L is selected from amine, amide, saturated or unsaturated, substituted or unsubstituted C<sub>1-600</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, wherein optional substituents are selected from any C<sub>1-20</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano and carbonyl and combinations thereof, and L is monomeric, oligomeric having oligomeric repeat of 2 to 30 or polymeric having polymeric repeat in excess of 30 up to 300;

Tag is any tagging substrate;

m are each independently selected from a whole number integer from 1 to 3;

p is 0 to 3

wherein one or more of each -Tag in one or more of each library compound is a fluorophore entity -Fl, whereby the library comprises compounds of which one or more or all of which compounds are of formula I'



**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

wherein linking is at same or different linking sites in compounds comprising different Lig, J<sub>L</sub>, L J<sub>T</sub> and/or – Tag and is at different linking sites in compounds comprising same Lig, J<sub>L</sub>, L J<sub>T</sub> and/or – Tag

wherein the or each F1 is selected from a red, near ir or blue dye and  
and the compound of formula I or I' retains pharmacological activity as a fluorescent  
GPCR ligand agonist or fluorescent GPCR ligand antagonist for GPCR receptor binding and  
activation or inhibition.

73. (Withdrawn-Previously Presented) A library of fluorescent ligands of formula I  
or I' or a compound thereof as hereinbefore defined in Claim 47 for visualising receptors or  
receptor binding, assessing pharmacological properties of the fluorescent ligand, in high  
throughput screening of novel chemical entities that bind to the target receptor, in inhibiting an  
intracellular enzyme or inhibiting a drug transporter or a substrate of a drug transporter, in  
studying drug transport or drugs suitable for transport or in distinguishing healthy or diseased  
tissue.

74. (Withdrawn-Previously Presented) A library of fluorescent ligands of formula I or  
I' or a compound thereof as hereinbefore defined in claim 47 or 64 for use in a method for  
GPCR receptor binding or inhibition, and visualisation comprising contacting the library or a  
compound thereof with a sample comprising live cell material comprising GPCRs, in manner to  
facilitate binding thereof, and detecting changes in fluorescence or location thereof.

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

75. (Withdrawn-Previously Presented) A library of fluorescent ligands of formula I or I' or a compound thereof for use as claimed in claim 74 wherein the library or compound thereof is a fluorescent ligand(s) which has affinity such that it binds semi-permanently or transiently and remains bound when unbound ligand is washed away.

76. (Withdrawn-Previously Presented) A library of fluorescent ligands of formula I or I' or a compound thereof for use as claimed in claim 74 wherein detecting a change in fluorescence is by means of confocal microscopy or fluorescence correlation spectroscopy.

77. (Withdrawn-Previously Presented) A library of fluorescent ligands of formula I or I' or a compound thereof for use as claimed in claim 74 wherein the library or compound thereof comprises fluorescent ligand agonist(s) which maintains its binding affinity and functional activity or is an antagonist which maintains its binding affinity on linking or when linked to fluorescent moiety Fl.

78. (Withdrawn-Previously Presented) A kit comprising a library or a compound of formula I or I' as claimed in claim 47 or 64 and a target therefor provided as cell derived material selected from a cell line, expressing a GPCR, membrane containing these proteins derived from such a cell line, solubilised receptor, or GPCR array from that cell line.

79. (Withdrawn-Previously Presented) Kit as claimed in Claim 78 wherein the cell derived material is provided in one of three forms: (1) from cells expressing a green fluorescent protein tagged receptor, (2) from cells expressing an epitope tag for a commercially available

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

fluorescent antibody or (3) a wild-type protein for which a specific fluorescent antibody is also provided.

80-82. (Cancelled).

83. (Withdrawn-Previously Presented) Library as claimed in Claim 55 wherein:  
Lig.a comprises linking functionality J<sub>L</sub> which is amine, and is of the formula, in either of the following forms given:

Lig.a<sup>1</sup><sub>m</sub>



wherein Ra<sup>4</sup> comprises linking functionality J<sub>L</sub> and J<sub>T</sub> which is amine;

X<sup>1</sup> and X<sup>2</sup> are each O;


R.a<sup>3</sup> is H;

each of R.a<sup>1</sup> and R.a<sup>2</sup> is n-propyl;

R.a<sup>4</sup> is p- substituted phenyl wherein the substituent is heteroalkyl amide amine; and includes L which is C<sub>1-50</sub> alkyl optionally substituted by C<sub>1</sub> alkyl and including the formula –(CH<sub>2</sub>)<sub>n</sub> where n is 3 to 8, optionally including one or more heteroatoms –O;

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)

Lig.b comprises linking functionality J<sub>L</sub> which is amine, and is



wherein      ring substituents X.b<sup>1</sup> and X.b<sup>2</sup> are each OH;

ring heteroatom X.b<sup>3</sup> is -O- ;


Rb<sup>1</sup> is CONHEt or CH<sub>2</sub>OH;

and each of R.b<sup>2</sup> and R.b<sup>3</sup> is H;

Rb<sup>4</sup> is H;

Rb<sup>5</sup> comprises linking functionality J<sub>T</sub> which is amino, and linker L.b selected from saturated C<sub>1-12</sub> aliphatic and C<sub>6-24</sub>- aromatic, optionally substituted by one or more C<sub>1</sub> alkyl and optionally including one or more heteroatoms O or cyclic groups;

Lig.c comprises linking functionality J<sub>L</sub> which is amine and is




as a racemate or as one of its optically active isomers wherein \* indicates an optically active centre,

Rc<sup>1</sup> is m-, p- dihydroxyphenyl; and



**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

R<sup>d</sup><sup>2</sup> comprises linking functionality J<sub>T</sub> which is amine, and linker L.c which is selected from C<sub>1-12</sub> straight chain alkyl, C<sub>6-12</sub> cycloalkyl or aryl and combinations thereof optionally comprising one or more heteroatoms O and optionally substituted by C<sub>1</sub> aliphatic;

or Lig.d comprises a linking functionality J<sub>L</sub> which is amine and is



as a racemate or as one of its optically active isomers wherein \* indicates an optically active centre,



R<sup>d</sup><sup>1</sup> is selected from the structures


and a substituted C<sub>1-20</sub> spiro aromatic ring system comprising a single aromatic ring and a heteroaryl and optionally halo substituted; and

R<sup>d</sup><sup>2</sup> comprises linking functionality J<sub>T</sub> which is amine, and linker L.d which is selected from C<sub>1-12</sub> straight chain alkyl, C<sub>6-12</sub> cycloalkyl or aryl and combinations thereof optionally comprising one or more heteroatoms O and optionally substituted by C<sub>1</sub> aliphatic; or R<sup>d</sup><sup>2</sup> is C<sub>1-6</sub> straight


**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

chain alkyl including ether O and substituted by C<sub>6-10</sub> aryl which is OH and oxo substituted and comprises linker L.d as hereinbefore defined.

84. (Withdrawn-Previously Presented) Library as claimed in claim 83 wherein R.a<sup>4</sup>, R.b<sup>5</sup> or R.c<sup>2</sup> or R.d<sup>2</sup> comprises linking functionality J<sub>T</sub> which is amino, and linker L.a, L.b, L.c or L.d selected from (CH<sub>2</sub>)<sub>m</sub> wherein m is 3, 4, 6 or 8 or is in the range 3 to 8 or 2 to 12 optionally including one or more substituents C<sub>1</sub>, or J<sub>L</sub> L J<sub>T</sub> is mono or polyethylene glycol diamine; or  
R.c<sup>2</sup> or R.d<sup>2</sup> comprises linking functionality J<sub>T</sub> which is amino, and linker L.c or L.d selected from C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>Ph and mono amino menthane or the structure



or R.d<sup>2</sup> comprises the following OH substituted aryl structure wherein linking functionality J<sub>L</sub> is shown as amine, Ld is as hereinabove defined and includes J<sub>T</sub> which is amine:




85. (Cancelled).

86. (Withdrawn-Previously Presented) Library as claimed in Claim47 wherein F1 is selected from Texas Red™, Cy5.5 or Cy5 or analogues thereof, DY-630, DY-640, DY-650 or


**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

DY-655 or analogues thereof, ATTO 655 or ATTO 680 or analogues thereof, EvoBlue 30 or analogues thereof, Alexa 647 or analogues thereof, BODIPY 630/650 and analogues thereof including BODIPY 630/650 X.

87. (Withdrawn-Previously Presented) Library comprising a compound selected from the following structures wherein any optically active fluorescent ligand is present as a racemate or as one of its optically active isomers:




XAC – BODIPY 630/650 X




ABA-BY630


SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)



ABEA-BY630




APEA-BY 630




ABIPEA – BY630


SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)



and




Salmeterol BY 630/650




Clenbuterol BY 630/650


SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)



CGP12177-BY 630/650




Propranolol BY630/650



ICI118551-BY630/650

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)



Alprenolol-BY630/650

and wherein the library comprises pharmacological activity as a fluorescent GPCR ligand agonist or fluorescent GPCR ligand antagonist for GPCR receptor binding and activation or inhibition.

88. (Withdrawn-Previously Presented) Compound as claimed in Claim 67 wherein:  
Lig.a comprises linking functionality  $J_L$  which is amine, and is of the formula, in either of the following forms given:

Lig.a<sup>1</sup><sub>m</sub>



wherein  $Ra^4$  comprises linking functionality  $J_L$  and  $J_T$  which is amine;

$X^1$  and  $X^2$  are each O;


$Ra^3$  is H;

each of  $Ra^1$  and  $Ra^2$  is n-propyl;

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**


R.a<sup>4</sup> is p- substituted phenyl wherein the substituent is heteroalkyl amide amine; and includes L which is C<sub>1-50</sub> alkyl optionally substituted by C<sub>1</sub> alkyl and including the formula –(CH<sub>2</sub>)<sub>n</sub> where n is 3 to 8, optionally including one or more heteroatoms –O;

Lig.b comprises linking functionality J<sub>L</sub> which is amine, and is



wherein      ring substituents X.b<sup>1</sup> and X.b<sup>2</sup> are each OH;  
                ring heteroatom X.b<sup>3</sup> is -O- ;  
Rb<sup>1</sup>      is CONHET or CH<sub>2</sub>OH;  
and      each of R.b<sup>2</sup> and R.b<sup>3</sup> is H;  
Rb<sup>4</sup>      is H;  
Rb<sup>5</sup>      comprises linking functionality J<sub>T</sub> which is amino, and linker L.b selected from saturated C<sub>1-12</sub> aliphatic and C<sub>6-24</sub> aromatic, optionally substituted by one or more C<sub>1</sub> alkyl and optionally including one or more heteroatoms O or cyclic groups;

Lig.c comprises linking functionality J<sub>L</sub> which is amine and is




**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

as a racemate or as one of its optically active isomers wherein \* indicates an optically active centre,





Rc<sup>1</sup> is m-, p- dihydroxyphenyl; and

Rc<sup>2</sup> comprises linking functionality J<sub>T</sub> which is amine, and linker L.c which is selected from C<sub>1-12</sub> straight chain alkyl, C<sub>6-12</sub> cycloalkyl or aryl and combinations thereof optionally comprising one or more heteroatoms O and optionally substituted by C<sub>1</sub> aliphatic;

or Lig.d comprises a linking functionality J<sub>L</sub> which is amine and is



as a racemate or as one of its optically active isomers wherein \* indicates an optically active centre,




Rd<sup>1</sup> is selected from the structures

and a substituted C<sub>1-20</sub> spiro aromatic ring system comprising a single aromatic ring and a heteroaryl and optionally halo substituted; and


**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

Rd<sup>2</sup> comprises linking functionality J<sub>T</sub> which is amine, and linker L.d which is selected from C<sub>1-12</sub> straight chain alkyl, C<sub>6-12</sub> cycloalkyl or aryl and combinations thereof optionally comprising one or more heteroatoms O and optionally substituted by C<sub>1</sub> aliphatic; or Rd<sup>2</sup> is C<sub>1-6</sub> straight chain alkyl including ether O and substituted by C<sub>6-10</sub> aryl which is OH and oxo substituted and comprises linker L.d as hereinbefore defined,  
with the proviso that the compound is not a compound excluded in Claim 47.

89. (Withdrawn-Previously Presented) Compound as claimed in Claim 88 wherein R.a<sup>4</sup>, R.b<sup>5</sup> or R.c<sup>2</sup> or R.d<sup>2</sup> comprises linking functionality J<sub>T</sub> which is amino, and linker L.a, L.b, L.c or L.d selected from (CH<sub>2</sub>)<sub>m</sub> wherein m is 3, 4, 6 or 8 or is in the range 3 to 8 or 2 to 12 optionally including one or more substituents C<sub>1</sub>, or J<sub>L</sub> L J<sub>T</sub> is mono or polyethylene glycol diamine; or  
R.c<sup>2</sup> or R.d<sup>2</sup> comprises linking functionality J<sub>T</sub> which is amino, and linker L.c or L.d selected from C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>Ph and mono amino menthane or the structure



or Rd<sup>2</sup> comprises the following OH substituted aryl structure wherein linking functionality J<sub>L</sub> is shown as amine, Ld is as hereinabove defined and includes J<sub>T</sub> which is amine:




**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

90. (Cancelled).


91. (Previously Presented) Compound as claimed in Claim 64 wherein F1 is selected from TEXAS RED™ sulforhodamine 101 acid chloride, Cy5.5 or Cy5 or analogues thereof, DY-630, DY-640, DY-650 or DY-655 or analogues thereof, ATTO 655 or ATTO 680 or analogues thereof, EVOBLUE™30 oxazine based dye or analogues thereof, Alexa 647 or analogues thereof, BODIPY™ 630/650 6-(((4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)styryloxy)acetyl and analogues thereof including BODIPY™ 630/650-X 6-(((4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)styryloxy)acetyl)amino hexanoyl.

92. (Withdrawn-Previously Presented) Compound as given in the following structures wherein any optically active fluorescent ligand is present as a racemate or as one of its optically active isomers:




XAC – BODIPY 630/650 X


SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)



ABA-BY630




ABEA-BY630




APEA-BY 630


SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)



ABIPEA - BY630




And Salmeterol derivative - BY 630/650




Salmeterol BY 630/650


SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)



Clenbuterol BY 630/650




CGP12177-BY 630/650




Propranolol BY630/650

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)



ICI118551-BY630/650



Alprenolol-BY630/650


and wherein the compound comprises pharmacological activity as a fluorescent GPCR ligand agonist or fluorescent GPCR ligand antagonist for receptor binding and activation or inhibition.

93. (Withdrawn-Previously Presented) Library of tagged non-peptide ligands comprising moiety Lig and L selected from formula Lig.a-L.a- - Lig.e-L.e associated with a Tag which is an entity -Fl wherein the or each -Fl is selected from a red, near ir or blue dye and wherein:

Lig.a- is suitably of the formula, in either of the following forms given:

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)

Lig.a<sup>1</sup>-



Wherein X<sup>1</sup> and X<sup>2</sup> are each independently selected from H, =O, OR.a, NR.a, NHR.a;

X<sup>1</sup> and X<sup>2</sup> are each preferably =O;

each of R.a, R.a<sup>1</sup>, R.a<sup>2</sup> and R.a<sup>3</sup> independently is selected from H or C<sub>1-4</sub> linear or branched alkyl, preferably H, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl or isobutyl optionally mono or multi hydroxy or halo substituted, such as CH<sub>2</sub>OH, CH<sub>2</sub>F or CH<sub>2</sub>CHOHCH<sub>2</sub>OH;


R.a<sup>4</sup> is selected from a heteroatom O, S or substituted or unsubstituted amine or saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like;

preferably R.a<sup>4</sup> is selected from optionally substituted aryl, cycloalkyl, alkyl, ketone, (di)amine, (di)amide, more preferably optionally substituted alkoxy, cycloalkyl, amine, amide, carboxylic acid or optionally o-, m- or p- substituted phenyl wherein substituents include aryl, alkyl, cycloalkyl, heteroaryl or heteroalkyl,

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)

amine, amide, carboxyl, carbonyl etc, for example is cyclohexyl, cyclopentyl, ethoxy,  $(\text{CH}_2)_2\text{PhPh}$ ,  $\text{CH}_2\text{Ph}$ ,  $\text{CONH}(\text{CH}_2)\text{nCONH}$ ,  $\text{CH}_2\text{CONH}(\text{CH}_2)_2\text{NH}$ ,  $\text{CH}_2\text{PhNHCOC}_2$ ,  $\text{CH}_2\text{CH}_2\text{OCOCH}_2$ , succinimidyl ester,  $\text{NHCOC}_2$ ,  $\text{CH}_2(\text{CH}_3)\text{NCOCH}_2$ ,  $\text{H}_2\text{N}(\text{CH}_2)_2\text{NHCOC}_2$ ,  $\text{H}_2\text{N}(\text{CH}_2)_8\text{NHCOC}_2$ ,  $\text{H}_2\text{NNHCOC}_2$ ,  $\text{CH}_2\text{CONH}(\text{CH}_2)_2\text{NHCOC}_2$ ,  $\text{HOPhCH}_2\text{N}(\text{CH}_2\text{CH}_3.\text{HOAc})(\text{CH}_2)_2\text{NHCOC}_2$ , heterocyclic- $(\text{CH}_2)_4\text{CONH}(\text{CH}_2)_2\text{NHCOC}_2$ , heterocyclic- $\text{NHCON}(\text{heterocyclic})\text{COCH}_2$  and the like;

or Lig.a- is of the formula Lig.a<sup>2-</sup>



wherein each of C.A1 and C.A2 is independently selected from aryl, heteroaryl, cyloalkyl and heterocyclic, more preferably from phenyl, or aryl containing 1 or 2 ring heteroatoms, or heterocyclic containing 1 ring heteroatom and/or 1 ring -C=C- group;

Each of up to seven R.a<sup>5</sup> is a substituent of a ring carbon or a ring heteroatom and: is independently selected from H, halo, hydroxy, thiol, amine, COOH, hydrazine, cyano, saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, and wherein optional substituents are


**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like, such as =O, OCH<sub>3</sub>, CH<sub>2</sub>Ph(OCH<sub>3</sub>)<sub>2</sub>, O(CH<sub>2</sub>)<sub>3</sub>CON(CH<sub>3</sub>)<sub>2</sub>, hex, N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, c.hex, COOCH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>; or any two or more of R.a<sup>5</sup> form a one, two or three ring fused cyclic structure, preferably comprising a fused 3 ring aryl, 5-heterocyclic, 6-heterocyclic structure having 4 ring atoms common with the fused bicyclic Lig.a<sup>2</sup> structure; and R.a<sup>6</sup> is a moiety as defined for R.a<sup>5</sup> above;

and -L.a- is as hereinbefore defined for -L- and is suitably of formula -L.I- or -L.II- as hereinbefore defined, more preferably is selected from amino acid or amide such as a peptide or polypeptide for example gly or gly<sub>3</sub>, alkyl of formula -(CH<sub>2</sub>)<sub>n</sub> where n is 3 to 8, preferably 3, 4 or 6, optionally including one or more heteroatoms or unsaturated groups, such as -O- or -S- or -CH=CH- and the like:

Lig.b is suitably of the formula Lig.b

Lig.b



**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

wherein ring substituents X.b<sup>1</sup> and X.b<sup>2</sup> are independently selected from hydrocarbon such as

alkyl or SR<sub>X</sub>, NR<sub>X,2</sub> and OR<sub>X</sub> wherein (each) R<sub>X</sub> is selected from H, C<sub>1</sub>-salkyl,

alkenyl;

ring heteroatom X.b<sup>3</sup> is selected from -S-, -O- and -CH<sub>2</sub>-;

Rb<sup>1</sup> is selected from saturated or unsaturated, substituted or unsubstituted C<sub>1-4</sub> aliphatic, or C<sub>1-3</sub> alicyclic optionally including one or more heteroatoms N, O, S, P, wherein substituent(s) are selected from one or more cycloalkyl, heterocyclic, hydroxy, oxo, halo, amine; preferably R.b<sup>1</sup> comprises a carbonyl substituted by H, alkyl or a linear or cyclic primary, secondary or tertiary amine, substituted C<sub>1-3</sub> alkyl, cycloalkyl or amide, more preferably cyclopropyl, or CONHC<sub>1-3</sub>alkyl such as CONHET or CH<sub>2</sub>OH

and each of R.b<sup>2</sup> and R.b<sup>3</sup> is selected from H, halo, hydroxy, thiol, amine, COOH, CHO, hydrazine, cyano or saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like, preferably from H, halo or hydroxy, preferably H or Cl;

Rb<sup>4</sup> is H;


-L.b- is as hereinbefore defined for -L-, more preferably saturated and unsaturated substituted or unsubstituted C<sub>1-12</sub> aliphatic or C<sub>1-24</sub> aromatic as defined for -L-

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

preferably including one or more heteroatoms O, S or N, cyclic or heterocyclic groups, more preferably is of formula -L.I- or -L.II- as hereinbefore defined, most preferably is -(CH<sub>2</sub>)<sub>m</sub> wherein m is 2 to 12, preferably 3, 4, 6 or 8, or is -(Ph-CH<sub>2</sub>CONH)<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>-;

Lig.c is suitably a non-peptide of the formula


Lig.c            HOC\*(R.c<sup>1</sup>)CH<sub>2</sub>NH-R.c<sup>2</sup>-



Where \* indicates an optically active centre and

Wherein R.c<sup>1</sup> is C<sub>6-14</sub> aryl optionally including one or more heteroatoms selected from H, O, optionally substituted by OH, Hal eg Cl, NH<sub>2</sub>, NHC<sub>1-3</sub>alkyl, sulphonamide, oxoamine (-CONH<sub>2</sub>) and the like, more preferably mono, di or tri substituted phenyl or quinoline wherein substituents include OH, Cl or NH<sub>2</sub>, more preferably m-CH<sub>2</sub>OH, p-OH phenyl, m-,p-dihydroxy phenol or m-,m-dihydroxyphenol, m-,m-diCl, p-NH<sub>2</sub> phenol, p-OH, m-CONH<sub>2</sub> phenol or 5-OH, 8-quinoline and the like, such as


SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)



R.c<sup>2</sup> is selected from saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub>, preferably C<sub>1-12</sub>, branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any optionally substituted C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like and combinations thereof;  
Preferably R.c<sup>2</sup> is selected from C<sub>1-6</sub> branched or straight chain aliphatic, C<sub>6-10</sub> araliphatic optionally substituted by OH and optionally including heteroatoms selected from N,O, preferably including an ether O, such as selected from -(CH<sub>2</sub>)<sub>6</sub>OCH((CH<sub>2</sub>)<sub>3</sub>Ph), CHCH<sub>3</sub>(CH<sub>2</sub>)<sub>2</sub>Ph, CHCH<sub>3</sub>CH<sub>2</sub>PhOH, C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>; -L.c- is as hereinbefore defined for -L- and is suitably of formula -L.I- or -L.II- as hereinbefore defined, more preferably is selected from C<sub>1-12</sub> alkyl, amide etc;

Lig.d is suitably a non-peptide of the formula

Lig.d R.d<sup>1</sup> OCH<sub>2</sub>C\*HOHCH<sub>2</sub>NH-R.d<sup>2</sup>-#




**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

Where \* indicates an optically active centre and where # indicates the site of linking to the fluorescent tagging moiety


Wherein R.d<sup>1</sup> is saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like;

Preferably R.d<sup>1</sup> is substituted or unsubstituted C<sub>1-24</sub> aralkyl or heteroaralkyl, including single ring and fused ring systems with (hetero)aryl or cycloalkyl rings, wherein optional substituents include C<sub>1-6</sub> alkyl, alkoxy, ether, carbonyl, alkenyl, amine, amide each optionally carbonyl, amide, halo or OH substituted, or halo such as chloro or OH, preferably R.d<sup>1</sup> is unsubstituted or substituted alkyl, alkenyl, halo, amine, amide, carbonyl, ketone, ether substituted phenyl or naphthyl, illustrated as follows, most preferably mono-, di-, tri- or tetra substituted mono or polycyclic fused aryl or cycloaryl or heterocycloaryl such as phenyl, carbazole or structures shown below or spiro ring systems, most preferably mono-, di-, tri- or tetra alkoxyalkyl, alkoxyalkoxyalkyl or CF<sub>3</sub> substituted phenyl or unsubstituted or monosubstituted naphthalene or 5,6 ring systems most preferably of the structures:

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)



R.d<sup>2</sup> is substituted or unsubstituted amine, saturated or unsaturated, substituted or unsubstituted C<sub>1-12</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like, more preferably amine, C<sub>1-6</sub> branched or straight chain alkyl optionally including ether O, and optionally substituted by C<sub>6-10</sub> aryl, for example of the formula:



i.pr, i.bu, CH<sub>2</sub>CH<sub>2</sub>O (m-CONH<sub>2</sub>, p-OH) phenol, CH<sub>2</sub>CH<sub>2</sub>O (o-OCH<sub>3</sub>) phenol

-L.d- is as hereinbefore defined for -L- and is suitably of formula -L.I- or -L.II- as hereinbefore defined, more preferably is as hereinbefore defined for -L.a-;



SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
 U.S. Application No. 10/551,475 (Q111431)

Lig.e comprises a cell permeant moiety or is associated with a cell permeant L or Fl moiety and is suitably of the formula , in either of the following forms given:

Lig.e<sup>1</sup>



wherein h is selected from



each optionally substituted by R.e<sup>3</sup> – R.e<sup>4</sup> wherein R.e<sup>1</sup> – R.e<sup>4</sup> are as R.a<sup>1</sup> – R.a<sup>4</sup> defined above or in which R.e<sup>3</sup> is C<sub>5</sub>-linear or branched alkyl, optionally mono or multi hydroxy or halo substituted or is aryl optionally substituted by alkoxy, sulfonyl and the like eg ortho-OEt, meta-SO<sub>2</sub>N and NCH<sub>3</sub>  
 each X is independently selected from H, =O, -OR.e<sup>2</sup>, =N, HN, NR.e<sup>5</sup>, HR.e<sup>6</sup>, and aryl optionally substituted by ether; or X is aryl optionally alkyl or alkoxy substituted such as Ph-ortho-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> ;


**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

and where R.e<sup>5</sup> is as defined above for R.e<sup>1</sup> above or forms a fused cyclic ring together with the adjacent ring N atom; preferably 1 or 2 fused 5 membered cyclic rings;

and R.e<sup>6</sup> is as defined above for R.e<sup>1</sup> above or is selected from optionally substituted phenyl wherein optional substituents include ether such as o-ethoxy or o-propoxy, alkyl, OH and the like, sulphonyl, carbonyl and the like substituted by heterocyclic, or cyclic C<sub>5-8</sub> alkyl such as methyl, piperazinyl, sulphonyl and the like;

or Lig.c is of the formula Lig.c<sup>2</sup>

Lig.c<sup>2</sup>




Wherein each spiro ring optionally comprises zero or one or more heteroatoms h which are preferably N, more preferably zero or 1 N heteroatom and

comprises zero, 1 or 2 N heteroatoms and is unsaturated or comprises one or two -C=C- or -C=N- groups; and wherein each ring is optionally substituted by one or more oxo, CO, COOH, C<sub>1-6</sub> alkyl or linear or cyclic alkoxy such as methoxy, ethoxy or cyclopentyloxy optionally substituted by one or more oxo, CO, COOH, CN, or C<sub>1-6</sub> alicyclic or amine groups, amine or one or more spiro or fused heterocycles;

or Lig.c is of the formula Lig.c<sup>3</sup>

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)



Wherein each of C.<sub>E1</sub> and C.<sub>E2</sub> is independently selected from aryl, heteroaryl, cyloalkyl and heterocyclic, more preferably from phenyl, or aryl containing 1 or 2 ring heteroatoms, or heterocyclic containing 1 ring heteroatom and/or 1 ring -C=C- group;

Each of up to seven R.e<sup>11</sup> is a substituent of a ring carbon or a ring heteroatom and:

is independently selected from saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, and wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like, such as =O, OCH<sub>3</sub>, CH<sub>2</sub>Ph(OCH<sub>3</sub>)<sub>2</sub>, O(CH<sub>2</sub>)<sub>2</sub>CON(CH<sub>3</sub>)<sub>2</sub>c.hex, N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, c.hex, COOCH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>;

or any two or more of R.e<sup>11</sup> form a one, two or three ring fused cyclic structure, preferably comprising a fused 3 ring aryl, 5-heterocyclic, 6-heterocyclic structure having 4 ring atoms common with the fused bicyclic Lig.e<sup>3</sup> structure;

and R.e<sup>12</sup> is a moiety as defined for R.e<sup>11</sup> above;

Preferably Lig.e is of the formula Lig.e<sup>1</sup> as hereinbefore defined in particular

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

where R.e<sup>2</sup> and R.e<sup>3</sup> are respectively propyl and butyl;

-L.e- is suitably as hereinbefore defined for -L.a-.


94. (Withdrawn-Previously Presented) Library as claimed in claim 93 wherein the or each Fl is selected from the following dyes: Texas red™, coumarin and derivatives, Cascade Blue™, EvoBlue and fluorescent derivatives thereof, pyrenes and pyridyloxazole derivatives, the cyanine dyes, the dyomics (DY dyes and ATTO dyes) and fluorescent derivatives thereof, the Alexafluor dyes and derivatives, BDI dyes including the commercially available Bodipy™ dyes, pyrenes, anthracenes, acridines, fluorescent phycobiliproteins and their conjugates and fluoresceinated microbeads, and Texas Red derivatives, coupled to amine groups using the isocyanate, succinimidyl ester or dichlorotriazinyl-reactive groups.

95. (Withdrawn-Previously Presented) Compound which is a tagged non-peptide ligand comprising moiety Lig and L selected from formula Lig.a-L.a- - Lig.e-L.e associated with a Tag which is an entity -Fl wherein -Fl is selected from a red, near ir or blue dye and wherein and the compound comprises pharmacological activity as a fluorescent GPCR ligand agonist or fluorescent GPCR ligand antagonist for GPCR receptor binding and activation or inhibition.

Lig.a- is suitably of the formula, in either of the following forms given:

Lig.a<sup>1</sup>-

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)



Wherein X<sup>1</sup> and X<sup>2</sup> are each independently selected from H, =O, OR.a, NR.a, NHR.a;  
X<sup>1</sup> and X<sup>2</sup> are each preferably =O;  
each of R.a, R.a<sup>1</sup>, R.a<sup>2</sup> and R.a<sup>3</sup> independently is selected from H or C<sub>1-4</sub> linear or branched alkyl, preferably H, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl or isobutyl optionally mono or multi hydroxy or halo substituted, such as CH<sub>2</sub>OH, CH<sub>2</sub>F or CH<sub>2</sub>CHOHCH<sub>2</sub>OH;  
R.a<sup>4</sup> is selected from a heteroatom O, S or substituted or unsubstituted amine or saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like;  
preferably R.a<sup>4</sup> is selected from optionally substituted aryl, cycloalkyl, alkyl, ketone, (di)amine, (di)amide, more preferably optionally substituted alkoxy, cycloalkyl, amine, amide, carboxylic acid or optionally o-, m- or p- substituted phenyl wherein substituents include aryl, alkyl, cycloalkyl, heteroaryl or heteroalkyl, amine, amide, carboxyl, carbonyl etc, for example is cyclohexyl, cyclopentyl, ethoxy, (CH<sub>2</sub>)<sub>2</sub>PhPh, CH<sub>2</sub>Ph, CONH(CH<sub>2</sub>)<sub>n</sub>CONH, CH<sub>2</sub>CONH(CH<sub>2</sub>)<sub>2</sub>NH,

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)

CH<sub>2</sub>PhNHCOCH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>OCOCH<sub>2</sub>, succinimidyl ester, NHCOCH<sub>2</sub>,

CH<sub>2</sub>(CH<sub>3</sub>)NCOCH<sub>2</sub>, H<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>NHCOCH<sub>2</sub>, H<sub>2</sub>N(CH<sub>2</sub>)<sub>8</sub>NHCOCH<sub>2</sub>,


H<sub>2</sub>NNHCOCH<sub>2</sub>, CH<sub>2</sub>CONH(CH<sub>2</sub>)<sub>2</sub>NHCOCH<sub>2</sub>,

HOPhCH<sub>2</sub>N(CH<sub>2</sub>CH<sub>3</sub>.HOAc)(CH<sub>2</sub>)<sub>2</sub>NHCOCH<sub>2</sub>,

heterocyclic-(CH<sub>2</sub>)<sub>4</sub>CONH(CH<sub>2</sub>)<sub>2</sub>NHCOCH<sub>2</sub>,

heterocyclic-NHCON(heterocyclic)COCH<sub>2</sub> and the like;

or Lig.a- is of the formula Lig.a<sup>2</sup>-



wherein each of C.<sub>A1</sub> and C.<sub>A2</sub> is independently selected from aryl, heteroaryl, cyloalkyl and heterocyclic, more preferably from phenyl, or aryl containing 1 or 2 ring heteroatoms, or heterocyclic containing 1 ring heteroatom and/or 1 ring -C=C- group;

Each of up to seven R.a<sup>5</sup> is a substituent of a ring carbon or a ring heteroatom and:

is independently selected from H, halo, hydroxy, thiol, amine, COOH, hydrazine, cyano, saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, and wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine,


SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)

hydrazine, oxo, cyano, and the like, such as =O, OCH<sub>3</sub>, CH<sub>2</sub>Ph(OCH<sub>3</sub>)<sub>2</sub>, O(CH<sub>2</sub>)<sub>3</sub>CON(CH<sub>3</sub>)c.hex, N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, c.hex, COOCH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>;  
or any two or more of R.a<sup>5</sup> form a one, two or three ring fused cyclic structure, preferably comprising a fused 3 ring aryl, 5-heterocyclic, 6-heterocyclic structure having 4 ring atoms common with the fused bicyclic Lig.a<sup>2</sup>structure;  
and R.a<sup>6</sup> is a moiety as defined for R.a<sup>5</sup> above;

and -L.a- is as hereinbefore defined for -L- and is suitably of formula -L.I- or -L.II- as hereinbefore defined, more preferably is selected from amino acid or amide such as a peptide or polypeptide for example gly or gly<sub>3</sub>, alkyl of formula -(CH<sub>2</sub>)<sub>n</sub> where n is 3 to 8, preferably 3, 4 or 6, optionally including one or more heteroatoms or unsaturated groups, such as -O- or -S- or -CH=CH- and the like;

Lig.b is suitably of the formula Lig.b

Lig.b



wherein ring substituents X.b<sup>1</sup> and X.b<sup>2</sup> are independently selected from hydrocarbon such as alkyl or SR<sub>X</sub>, NR<sub>X.2</sub> and OR<sub>X</sub> wherein (each) R<sub>X</sub> is selected from H, C<sub>1-5</sub>alkyl, alkenyl;

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

ring heteroatom X.b<sup>3</sup> is selected from -S-, -O- and -CH<sub>2</sub>-;

Rb<sup>1</sup> is selected from saturated or unsaturated, substituted or unsubstituted C<sub>1-4</sub> aliphatic, or C<sub>1-3</sub> alicyclic optionally including one or more heteroatoms N, O, S, P, wherein substituent(s) are selected from one or more cycloalkyl, heterocyclic, hydroxy, oxo, halo, amine; preferably R.b<sup>1</sup> comprises a carbonyl substituted by H, alkyl or a linear or cyclic primary, secondary or tertiary amine, substituted C<sub>1-3</sub> alkyl, cycloalkyl or amide, more preferably cyclopropyl, or CONHC<sub>1-3</sub>alkyl such as CONHET or CH<sub>2</sub>OH

and each of R.b<sup>2</sup> and R.b<sup>3</sup> is selected from H, halo, hydroxy, thiol, amine, COOH, CHO, hydrazine, cyano or saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like, preferably from H, halo or hydroxy, preferably H or Cl;

Rb<sup>4</sup> is H;


-L.b- is hereinbefore defined for -L-, more preferably saturated and unsaturated substituted or unsubstituted C<sub>1-12</sub> aliphatic or C<sub>1-24</sub> aromatic as defined for -L- preferably including one or more heteroatoms O, S or N, cyclic or heterocyclic groups, more preferably is of formula -L.I- or -L.II- as hereinbefore defined, most

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

preferably is  $-(\text{CH}_2)_m$  wherein m is 2 to 12, preferably 3, 4, 6 or 8, or is  $-(\text{Ph}-\text{CH}_2\text{CONH})_2(\text{CH}_2)_2-$ ;


Lig.c is suitably a non-peptide of the formula

Lig.c  $\text{HOC}^*(\text{R.c}^1)\text{CH}_2\text{NH-R.c}^2-$



Where \* indicates an optically active centre and

Wherein R.c<sup>1</sup> is C<sub>6-14</sub> aryl optionally including one or more heteroatoms selected from H, O, optionally substituted by OH, Hal eg Cl, NH<sub>2</sub>, NHC<sub>1-3</sub>alkyl, sulphonamide, oxoamine (-CONH<sub>2</sub>) and the like, more preferably mono, di or tri substituted phenyl or quinoline wherein substituents include OH, Cl or NH<sub>2</sub>, more preferably m-CH<sub>2</sub>OH, p-OH phenyl, m-,p-dihydroxy phenol or m-,m-dihydroxyphenol, m-,m-diCl, p-NH<sub>2</sub> phenol, p-OH, m-CONH<sub>2</sub> phenol or 5-OH, 8-quinoline and the like, such as



**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**


R.c<sup>2</sup> is selected from saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub>, preferably C<sub>1-12</sub>, branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any optionally substituted C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like and combinations thereof;

Preferably R.c<sup>2</sup> is selected from C<sub>1-6</sub> branched or straight chain aliphatic, C<sub>6-10</sub> araliphatic optionally substituted by OH and optionally including heteroatoms selected from N,O, preferably including an ether O, such as selected from -(CH<sub>2</sub>)<sub>6</sub>OCH((CH<sub>2</sub>)<sub>3</sub>Ph), CHCH<sub>3</sub>(CH<sub>2</sub>)<sub>2</sub>Ph, CHCH<sub>3</sub>CH<sub>2</sub>PhOH, C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>,

-L.c- is as hereinbefore defined for -L- and is suitably of formula -L.I- or -L.II- as hereinbefore defined, more preferably is selected from C<sub>1-12</sub> alkyl, amide etc;

Lig.d is suitably a non-peptide of the formula

Lig.d R.d<sup>1</sup> OCH<sub>2</sub>C\*HOHCH<sub>2</sub>NH-R.d<sup>2</sup>#



Where \* indicates an optically active centre and where # indicates the site of linking to the fluorescent tagging moiety


**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

Wherein R.d<sup>1</sup> is saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like;


Preferably R.d<sup>1</sup> is substituted or unsubstituted C<sub>1-24</sub> aralkyl or heteroaralkyl, including single ring and fused ring systems with (hetero)aryl or cycloalkyl rings, wherein optional substituents include C<sub>1-6</sub> alkyl, alkoxy, ether, carbonyl, alkenyl, amine, amide each optionally carbonyl, amide, halo or OH substituted, or halo such as chloro or OH, preferably R.d<sup>1</sup> is unsubstituted or substituted alkyl, alkenyl, halo, amine, amide, carbonyl, ketone, ether substituted phenyl or naphthyl, illustrated as follows, most preferably mono-, di-, tri- or tetra substituted mono or polycyclic fused aryl or cycloaryl or heterocycloaryl such as phenyl, carbazole or structures shown below or spiro ring systems, most preferably mono-, di-, tri- or tetra alkoxyalkyl, alkoxyalkoxyalkyl or CF<sub>3</sub> substituted phenyl or unsubstituted or

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)

monosubstituted naphthalene or 5,6 ring systems most preferably of the structures:



R.d<sup>2</sup> is substituted or unsubstituted amine, saturated or unsaturated, substituted or unsubstituted C<sub>1-12</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like, more preferably amine, C<sub>1-6</sub> branched or straight chain alkyl optionally including ether O, and optionally substituted by C<sub>6-10</sub> aryl, for example of the formula:



i.pr, i.bu, CH<sub>2</sub>CH<sub>2</sub>O (m-CONH<sub>2</sub>, p-OH) phenol, CH<sub>2</sub>CH<sub>2</sub>O (o-OCH<sub>3</sub>) phenol

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)**


-L.d- is as hereinbefore defined for -L- and is suitably of formula -L.I- or -L.II- as hereinbefore defined, more preferably is as hereinbefore defined for -L.a-;

Lig.e comprises a cell permeant moiety or is associated with a cell permeant L or Fl moiety and is suitably of the formula , in either of the following forms given:

Lig.e<sup>1</sup>



wherein  $h$  is selected from



each optionally substituted by R.e<sup>3</sup> – R.e<sup>4</sup> wherein R.e<sup>1</sup> – R.e<sup>4</sup> are as R.a<sup>1</sup> – R.a<sup>4</sup> defined above or in which R.e<sup>3</sup> is C<sub>5</sub>-9 linear or branched alkyl, optionally mono or multi hydroxy or halo substituted or is aryl optionally substituted by alkoxy, sulfonyl and the like eg ortho-OEt, meta-SO<sub>2</sub>NHCH<sub>3</sub>

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**


each X is independently selected from H, =O, -OR.e<sup>2</sup>, =N, HN, NR.e<sup>5</sup>, HR.e<sup>6</sup>, and aryl optionally substituted by ether; or X is aryl optionally alkyl or alkoxy substituted such as Ph-ortho-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>;

and where R.e<sup>5</sup> is as defined above for R.e<sup>1</sup> above or forms a fused cyclic ring together with the adjacent ring N atom; preferably 1 or 2 fused 5 membered cyclic rings;


and R.e<sup>6</sup> is as defined above for R.e<sup>1</sup> above or is selected from optionally substituted phenyl wherein optional substituents include ether such as o-ethoxy or o-propoxy, alkyl, OH and the like, sulphonyl, carbonyl and the like substituted by heterocyclic, or cyclic C<sub>5-8</sub> alkyl such as methyl, piperazinyl, sulphonyl and the like;

or Lig.e is of the formula Lig.e<sup>2</sup>

Lig.e<sup>2</sup>




Wherein each spiro ring optionally comprises zero or one or more heteroatoms h which are preferably N, more preferably zero or 1 N heteroatom and



SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)

heteroatoms and is unsaturated or comprises one or two  $-C=C-$  or  $-C=N-$  groups; and wherein each ring is optionally substituted by one or more oxo, CO, COOH, C<sub>1-6</sub> alkyl or linear or cyclic alkoxy such as methoxy, ethoxy or cyclopentyloxy optionally substituted by one or more oxo, CO, COOH, CN, or C<sub>1-6</sub> alicyclic or amine groups, amine or one or more spiro or fused heterocycles;

or Lig.c is of the formula Lig.c<sup>3</sup>



Wherein each of C.E1 and C.E2 is independently selected from aryl, heteroaryl, cyloalkyl and heterocyclic, more preferably from phenyl, or aryl containing 1 or 2 ring heteroatoms, or heterocyclic containing 1 ring heteroatom and/or 1 ring  $-C=C-$  group;

Each of up to seven R.e<sup>11</sup> is a substituent of a ring carbon or a ring heteroatom and: is independently selected from saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, and wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like, such as =O,

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

OCH<sub>3</sub>, CH<sub>2</sub>Ph(OCH<sub>3</sub>)<sub>2</sub>, O(CH<sub>2</sub>)<sub>3</sub>CON(CH<sub>3</sub>)c.hex, N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, c.hex, COOCH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>;

or any two or more of R.c<sup>11</sup> form a one, two or three ring fused cyclic structure, preferably comprising a fused 3 ring aryl, 5-heterocyclic, 6-heterocyclic structure having 4 ring atoms common with the fused bicyclic Lig.e<sup>3</sup> structure;

and R.c<sup>12</sup> is a moiety as defined for R.c<sup>11</sup> above;

Preferably Lig.c is of the formula Lig.c<sup>1</sup> as hereinbefore defined in particular where R.c<sup>2</sup> and R.c<sup>3</sup> are respectively propyl and butyl;

-L.c- is suitably as hereinbefore defined for -L.a-.

96. (Withdrawn-Previously Presented) Compound as claimed in claim 95 wherein F1 is selected from the following dyes: Texas red<sup>TM</sup>, coumarin and derivatives, Cascade Blue<sup>TM</sup>, EvoBlue and fluorescent derivatives thereof, pyrenes and pyridyloxazole derivatives, the cyanine dyes, the dyomics (DY dyes and ATTO dyes) and fluorescent derivatives thereof, the Alexafluor dyes and derivatives, BDI dyes including the commercially available Bodipy<sup>TM</sup> dyes, pyrenes, anthracenes, acridines, fluorescent phycobiliproteins and their conjugates and fluoresccinated microbeads, and Texas Red derivatives, coupled to amine groups using the isocyanate, succinimidyl ester or dichlorotriazinyl-reactive groups.

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

97. (Withdrawn-Previously Presented) Process for the preparation of a library as claimed in Claim 59, wherein reactive groups  $Y_{\text{Lig}}$ ,  $Y_L$ ,  $Y_T$  have suitable reactive group functionalities for linking by addition or addition – elimination reaction.

98. (Withdrawn-Previously Presented) Process for the preparation of a compound as claimed in Claim 60, wherein reactive groups  $Y_{\text{Lig}}$ ,  $Y_L$ ,  $Y_T$  have suitable reactive group functionalities for linking by addition or addition – elimination reaction.

99. (Withdrawn-Previously Presented) Compound as claimed in Claim 64 wherein Lig is a ligand selected from any compound which is effective as an agonist or antagonist for an adenosine receptor, a beta-adrenoceptor, a muscarinic receptor, a histamine receptor, an opiate receptor, a cannabinoid receptor, a chemokine receptor, an alpha-adrenoceptor, a GABA receptor, a prostanoid receptor, a 5-HT (serotonin) receptor, an excitatory aminoacid receptor (glutamate), a dopamine receptor, a protease-activating receptor, a neurokinin receptor, an angiotensin receptor, an oxytocin receptor, a leukotriene receptor, a nucleotide receptor (purines and pyrimidines), a calcium-sensing receptor, a thyroid-stimulating hormone receptor, a neurotensin receptor, a vasopressin receptor, an olfactory receptor, a nucleobase receptor (adenosine), a lysophosphatidic acid receptor, a sphingolipid receptor, a tyramine receptor (trace amines), a free-fatty acid receptor and a cyclic nucleotide receptor; or wherein Lig is selected from

- a) xanthine like structures including XAC, theophylline, caffeine, theobromine, dyphilline, enprofylline; or fused biaryl structures including papaverine, dihydroquinolones, cilostamide, dipyridamole or vinpocetine; and analogues thereof;

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

- b) adenosine like structures including ADAC, NECA and analogues thereof;
- c) ethanolamine like structures including salmeterol, salbutamol, terbutaline, quinprenaline, labetalol, sotalol, bambuterol, fenoterol, reprotohol, tulobuterol, clenbuterol and analogues thereof;
- d) oxypropanolamine like structures including CGP12177, propranolol, practolol, acebutalol, betaxolol, ICI 118551, alprenolol, celiprolol (celectol), metoprolol (betaaloc), CGP20712A, atenolol, bisoprolol, misaprolol, carvedilol, bucindolol, esmolol, nadolol, nebivolol, oxprenolol, xamoterol, pindolol, timolol and analogues thereof;
- e) xanthine like structures including XAC, theophylline, caffeine, theobromine, dyphilline, enprofylline, sildenafil, EHNA (erythro-9-(2-hydroxyl-3-nonyl)adenine), zaprinast; or spiro bicyclic structures including bypyridines, amrinone; imidazolines, CI930; dihydropyridazinones, indolan, rolipram, SB207499; or fused biaryl structures including papaverine, dihydroquinolines, cilostamide, dipyridamole, vincocetine and analogues thereof.

100. (Withdrawn-Previously Presented) Compound as claimed in Claim 64 wherein each compound of formula I or I' comprises a moiety Lig and L as hereinbelow defined:

Wherein:

any optically active fluorescent ligand is present as a racemate or as one of its optically active isomers

Lig.a<sub>m</sub> is suitably of the formula, in either of the following forms given, including any of its



**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

possible linking configurations or sites:

Lig.a<sup>1</sup><sub>m</sub>

Wherein at least one or all of Ra<sup>1</sup> to Ra<sup>4</sup>, X<sup>1</sup> and X<sup>2</sup> comprise a linking site or functionality

J as hereinbefore defined

X<sup>1</sup> and X<sup>2</sup> are each independently selected from H, O, OR.a, NR.a, NHR.a;

X<sup>1</sup> and X<sup>2</sup> are each preferably O;

each of R.a<sup>1</sup>, R.a<sup>2</sup>, R.a<sup>3</sup> and R.a<sup>4</sup> independently is selected from H or C<sub>1-4</sub> linear or branched alkyl optionally mono or multi hydroxy or halo substituted;

R.a<sup>4</sup> is selected from a heteroatom O, S or substituted or unsubstituted amine or saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo and cyano;

including optionally substituted aryl, cycloalkyl, alkyl, ketone, (di)amine, (di)amide, alkoxy, cycloalkyl, carboxylic acid or optionally o-, m- or p-substituted phenyl wherein substituents include aryl, alkyl, cycloalkyl, heteroaryl or heteroalkyl, amine, amide, carboxyl, carbonyl or R.a<sup>4</sup> comprises cyclohexyl, cyclopentyl, ethoxy, (CH<sub>2</sub>)<sub>2</sub>PhPh, CH<sub>2</sub>Ph, CONH(CH<sub>2</sub>)<sub>n</sub>CONH, CH<sub>2</sub>CONH(CH<sub>2</sub>)<sub>2</sub>NH, CH<sub>2</sub>PhNHCOCH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>OCOCH<sub>2</sub>, succinimidyl ester,

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)

NHCOCH<sub>2</sub>, CH<sub>2</sub>(CH<sub>3</sub>)NCOCH<sub>2</sub>, H<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>NHCOCH<sub>2</sub>, H<sub>2</sub>N(CH<sub>2</sub>)<sub>8</sub>NHCOCH<sub>2</sub>,


H<sub>2</sub>NNHCOCH<sub>2</sub>, CH<sub>2</sub>CONH(CH<sub>2</sub>)<sub>2</sub>NHCOCH<sub>2</sub>,

HOPhCH<sub>2</sub>N(CH<sub>2</sub>CH<sub>3</sub>.HOAc)(CH<sub>2</sub>)<sub>2</sub>NHCOCH<sub>2</sub>,

heterocyclic-(CH<sub>2</sub>)<sub>4</sub>CONH(CH<sub>2</sub>)<sub>2</sub>NHCOCH<sub>2</sub> or

heterocyclic-NHCON(heterocyclic)COCH<sub>2</sub>;

or Lig.a is of the formula Lig.a<sup>2</sup>-



wherein at least one or all of Ra<sup>5</sup> to Ra<sup>6</sup>, or a cyclic C or heteroatom comprise a linking site or functionality J as hereinbefore defined,

each of C.A<sub>1</sub> and C.A<sub>2</sub> is independently selected from C<sub>5-6</sub> aryl, heteroaryl, cycloalkyl and heterocyclic, more preferably from phenyl, or aryl containing 1 or 2 ring heteroatoms, or heterocyclic containing 1 ring heteroatom and/or 1 ring -C=C- group;

Each of up to seven R.a<sup>5</sup> is a substituent of a ring carbon or a ring heteroatom and:

is independently selected from H, halo, hydroxy, thiol, amine, COOH, hydrazine, cyano, saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, and wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo =O or cyano; OCH<sub>3</sub>, CH<sub>2</sub>Ph(OCH<sub>3</sub>)<sub>2</sub>, O(CH<sub>2</sub>)<sub>3</sub>CON(CH<sub>3</sub>).c.hex, N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, c.hex, COOCH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>;

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**


or      any two or more of R.a<sup>5</sup> form a one, two or three ring fused cyclic structure, a fused 3 ring aryl, 5-heterocyclic or 6-heterocyclic structure having 4 ring atoms common with the fused bicyclic Lig.a<sup>2</sup> structure;

and     R.a<sup>6</sup> is a moiety as defined for R.a<sup>5</sup> above;

and L.a    is as hereinbefore defined for L or J<sub>L</sub> L J<sub>T</sub> or L.I or subformulae as hereinbefore defined, or is amino acid or amide including a peptide or polypeptide gly or gly<sub>3</sub>, alkyl of formula -(CH<sub>2</sub>)<sub>n</sub> where n is 3 to 8, optionally including one or more heteroatoms or unsaturated groups, including -O- or -S- or -CH=CH-;

Lig.b    is suitably of the formula Lig.b including any of its possible linking configurations or sites:

Lig.b



wherein      at least one or all of Rb<sup>1</sup> to Rb<sup>5</sup> or Xb<sup>1</sup> to Xb<sup>3</sup> comprise a linking site or functionality J as hereinbefore defined

ring substituents X.b<sup>1</sup> and X.b<sup>2</sup> are independently selected from hydrocarbon including alkyl or SR<sub>X</sub>, NR<sub>X,2</sub> and OR<sub>X</sub> wherein (each) R<sub>X</sub> is selected from H, C<sub>1-5</sub>alkyl, alkenyl;

ring heteroatom X.b<sup>3</sup> is selected from -S-, -O- and -CH<sub>2</sub>-;

Rb<sup>1</sup>    is selected from saturated or unsaturated, substituted or unsubstituted C<sub>1-4</sub> aliphatic, or C<sub>1-3</sub> alicyclic optionally including one or more heteroatoms N, O, S,

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

P, wherein substituent(s) are selected from one or more cycloalkyl, heterocyclic, hydroxy, oxo, halo, amine; or R.b<sup>1</sup> comprises a carbonyl substituted by H, alkyl or a linear or cyclic primary, secondary or tertiary amine, substituted C<sub>1-3</sub> alkyl, cycloalkyl or amide, cyclopropyl, or CONHC<sub>1-3</sub>alkyl including CONHET or CH<sub>2</sub>OH

and each of R.b<sup>2</sup> and R.b<sup>3</sup> is selected from H, halo, hydroxy, thiol, amine, COOH, CHO, hydrazine, cyano or saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo or cyano, preferably from H, halo or hydroxy;

Rb<sup>4</sup> is H;


Rb<sup>5</sup> is H or alkyl

L.b comprises a linking site or functionality J as hereinbefore defined; and is as hereinbefore defined for L or its subformulae, more preferably is saturated and unsaturated substituted or unsubstituted C<sub>1-12</sub> aliphatic or C<sub>1-24</sub> aromatic as defined for L optionally including one or more heteroatoms O, S or N, cyclic or heterocyclic groups, or is of formula L.I or its subformulae as hereinbefore defined, or is (CH<sub>2</sub>)<sub>m</sub> wherein m is 2 to 12, or is (Ph-CH<sub>2</sub>CONH)<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>;

Lig.c is of the formula Lig.c including any of its possible linking configurations or sites:

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**


Lig.c            HOC\*(R.c<sup>1</sup>)CH<sub>2</sub>NH-R.c<sup>2</sup>



where            at least one or all of Rc<sup>1</sup> to Rc<sup>2</sup> or OH, or a chain C or N comprise a linking site or functionality J as hereinbefore defined

\* indicates an optically active centre and

wherein R.c<sup>1</sup> is C<sub>6-14</sub> aryl optionally including one or more heteroatoms selected from H, O, optionally substituted by OH, Hal, NH<sub>2</sub>, NHC<sub>1-3</sub>alkyl, sulphonamide, oxoamine or (-CONH<sub>2</sub>), or is mono, di or tri substituted phenyl or quinoline wherein substituents include OH, Cl or NH<sub>2</sub>, or is m-CH<sub>2</sub>OH, p-OH phenyl, m-,p-dihydroxy phenol or m-,m-dihydroxyphenol, m-,m-diCl, p-NH<sub>2</sub> phenol, p-OH, m-CONH<sub>2</sub> phenol or 5-OH, 8-quinoline,




R.c<sup>2</sup> is selected from saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any optionally substituted C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)

more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo or cyano and combinations thereof;


or R.c<sup>2</sup> is selected from C<sub>1-6</sub> branched or straight chain aliphatic, C<sub>6-10</sub> araliphatic optionally substituted by OH and optionally including heteroatoms selected from N,O, optionally including an ether O, and is selected from -(CH<sub>2</sub>)<sub>6</sub>OCH((CH<sub>2</sub>)<sub>3</sub>Ph), CHCH<sub>3</sub>(CH<sub>2</sub>)<sub>2</sub>Ph, CHCH<sub>3</sub>CH<sub>2</sub>PhOH, C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>Ph or from the structures:



L.c is present as R.c<sup>2</sup> or comprises a linking site or functionality J as hereinbefore defined, and is as hereinbefore defined for L, formula L.I or its subformulae as hereinbefore defined, or is selected from C<sub>1-12</sub> alkyl, amide;

Lig.d is of the formula Lig.d including any of its possible linking configurations or sites:

Lig.d            R.d<sup>1</sup> OCH<sub>2</sub>C\*HOHCH<sub>2</sub>NH-R.d<sup>2</sup>




where at least one or all of Rd<sup>1</sup> to Rd<sup>2</sup> or OH, a chain C or N comprise a linking site or functionality J as hereinbefore defined

\* indicates an optically active centre


**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

wherein R.d<sup>1</sup> is saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo or cyano; or R.d<sup>1</sup> is substituted or unsubstituted C<sub>1-24</sub> aralkyl or heteroaralkyl, including single ring and fused ring systems with (hetero)aryl or cycloalkyl rings, wherein optional substituents include C<sub>1-6</sub> alkyl, alkoxy, ether, carbonyl, alkenyl, amine, amide each optionally carbonyl, amide, halo or OH substituted, or halo or OH, amine, amide, carbonyl, ketone, ether substituted phenyl or naphthyl, mono-, di-, tri- or tetra substituted mono or polycyclic fused aryl or cycloaryl or heterocycloaryl including phenyl, carbazole or structures shown below or spiro ring systems, mono-, di-, tri- or tetra alkoxyalkyl, alkoxyalkoxyalkyl or CF<sub>3</sub> substituted phenyl or unsubstituted or monosubstituted naphthalene or 5,6 ring systems:



**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

R.d<sup>2</sup> is substituted or unsubstituted amine, saturated or unsaturated, substituted or unsubstituted C<sub>1-12</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo or cyano, more preferably amine, C<sub>1-6</sub> branched or straight chain alkyl optionally including ether O, and optionally substituted by C<sub>6-10</sub> aryl, or of the formula:



L.d may be present as R.d<sup>2</sup> or may comprise a linking site or functionality J as hereinbefore defined and is as hereinbefore defined for L and its subformulae , formula L.I and its subformulae as hereinbefore defined, or is as hereinbefore defined for L.a;

Lig.e comprises a cell permeant moiety or is associated with a cell permeant L or Fl moiety or is of the formula , in either of the following forms given including any of its possible linking configurations or sites:



SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)

Lig.e<sup>1</sup>



wherein at least one or all of Re<sup>1</sup> to Re<sup>4</sup>, X and a ring C or N comprise a linking site or functionality J as hereinbefore defined

h is selected from



each optionally substituted by R.e<sup>3</sup> – R.e<sup>4</sup> wherein R.e<sup>1</sup> – R.e<sup>4</sup> are as R.a<sup>1</sup> – R.a<sup>4</sup> defined above or in which R.e<sup>3</sup> is C<sub>5-9</sub> linear or branched alkyl, optionally mono or multi hydroxy or halo substituted or is aryl optionally substituted by alkoxy or sulfonyl,

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

ortho-OEt, meta-SO<sub>2</sub>N                    NCH<sub>3</sub>


each X is independently selected from H, O, -OR.c<sup>2</sup>, N, HN, NR.c<sup>5</sup>, HR.c<sup>6</sup>, and  
aryl optionally substituted by ether; or X is aryl optionally alkyl or alkoxy  
substituted or is Ph-ortho-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>;

and where R.c<sup>5</sup> is as defined above for R.c<sup>1</sup> above or forms a fused cyclic ring  
together with the adjacent ring N atom, or 1 or 2 fused 5 membered cyclic rings;

and R.c<sup>6</sup> is as defined above for R.c<sup>1</sup> above or is selected from optionally substituted  
phenyl wherein optional substituents include ether, o-ethoxy or o-propoxy, alkyl  
or OH, sulphonyl or carbonyl substituted by heterocyclic, or cyclic C<sub>5-8</sub> alkyl,  
piperazinyl or sulphonyl;

or Lig.e is of the formula Lig.e<sup>2</sup>

Lig.e<sup>2</sup>



wherein at least one or all free ring atom or their substituents comprise a linking site or  
functionality J as hereinbefore defined

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)  
U.S. Application No. 10/551,475 (Q111431)


each spiro ring optionally comprises zero or one or more heteroatoms h

or (h)  comprises zero or 1 N heteroatom and  
5,6(h)  comprises

zero, 1 or 2 N heteroatoms and is unsaturated or comprises one or two -C=C- or -  
C=N- groups;

and wherein each ring is optionally substituted by one or more oxo, CO, COOH,  
C<sub>1-6</sub> alkyl or linear or cyclic alkoxy optionally substituted by one or more oxo,  
CO, COOH, CN, or C<sub>1-6</sub> alicyclic or amine groups, amine or one or more spiro or  
fused heterocycles;

or Lig.c is of the formula Lig.c<sup>3</sup>



wherein at least one or all of R.c<sup>11</sup> to R.c<sup>12</sup>, or a ring C or heteroatom or ring substituent  
comprise a linking site or functionality J as hereinbefore defined

each of C.E1 and C.E2 is independently selected from C<sub>5-6</sub> aryl, heteroaryl, cyloalkyl and  
heterocyclic, including phenyl, or aryl containing 1 or 2 ring heteroatoms,  
or heterocyclic containing 1 ring heteroatom and/or 1 ring -C=C- group;

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

each of up to seven R.c<sup>11</sup> is a substituent of a ring carbon or a ring heteroatom and:

is independently selected from saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, and wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo =O, or cyano, OCH<sub>3</sub>, CH<sub>2</sub>Ph(OCH<sub>3</sub>)<sub>2</sub>, O(CH<sub>2</sub>)<sub>3</sub>CON(CH<sub>3</sub>)c.hex, N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, c.hex, COOCH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>;

or any two or more of R.c<sup>11</sup> form a one, two or three ring fused cyclic structure, a fused 3 ring aryl, 5-heterocyclic or 6-heterocyclic structure having 4 ring atoms common with the fused bicyclic Lig.c<sup>3</sup> structure;

and R.c<sup>12</sup> is a moiety as defined for R.c<sup>11</sup> above;

L.c comprises a linking site or functionality J as hereinbefore defined and is suitably as hereinbefore defined for L.a.

101. (Previously Presented) The compound of Claim 64 wherein Lig and the compound of formula I or I' are selected from a GPCR ligand agonist or activator of GPCR receptor binding or functionality and a GPCR ligand antagonist or inhibitor of receptor binding or functionality.

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

102. (Previously Presented) The compound of Claim 64 which is an agonist which maintains its binding affinity and functional activity or is an antagonist which maintains its binding affinity on linking or when linked to fluorescent moiety Fl.

103. (Previously Presented) The compound of Claim 64 which has affinity such that it binds semi-permanently or transiently and remains bound when unbound ligand is washed away.

104. (Previously Presented) The compound of Claim 64 wherein L is selected from a short, medium or long chain moiety and prevents loss of affinity of ligand by distancing the Fl moiety from the Lig moiety, preventing interference with GPCR receptor binding.

105. (Previously Presented) The compound of Claim 64 wherein  $J_{Lm}$  L  $J_{Tm}$  comprises a polypeptide, peptide or polyether

106. (Previously Presented) The compound of formula I



or salt thereof

comprising ligand moiety Lig linked to tag moiety Tag via linker moiety L at linking site or linking functionality  $J_T$  and  $J_L$

wherein Lig is a ligand selected from a non-peptide GPCR ligand agonist and a non-peptide GPCR ligand antagonist, wherein the Lig comprises pharmacological activity as an agonist or antagonist for GPCR receptor binding and activation or inhibition,

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

L is selected from is selected from amine, amide, and saturated or unsaturated, substituted or unsubstituted C<sub>1-600</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof which comprise one or more heteroatoms selected from N, O, and optionally additionally S, P, wherein optional substituents are selected from any C<sub>1-20</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano and carbonyl and combinations thereof;

m are each independently selected from a whole number integer from 1 to 3;

p is 0 to 3

wherein -Tag is a fluorophore entity -Fl, whereby the compound is of formula I'

(LigJ<sub>L</sub>)<sub>m</sub> L (J<sub>T</sub> Fl)<sub>m</sub> (J<sub>T</sub> L (J<sub>L</sub> Lig)<sub>m</sub>)<sub>p</sub>

and the compound of formula I retains pharmacological activity as a fluorescent GPCR ligand agonist or fluorescent GPCR ligand antagonist for GPCR receptor binding and activation or inhibition,

wherein L is oligomeric having oligomeric repeat of 2 to 30 or polymeric having polymeric repeat in excess of 30 up to 300

with the proviso that:

when Lig is XAC ie in Lig.a when each of R.a<sup>1</sup> and R.a<sup>2</sup> is propyl, R.a<sup>3</sup> is H and R.a<sup>4</sup> is -Ph-OCH<sub>2</sub>CONH(CH<sub>2</sub>)<sub>2</sub>NH-, and L is gly3, Fl is not fluorescein;

when Lig is ADAC , ie R.b<sup>1</sup> is CH<sub>2</sub>OH, R.b<sup>2</sup> and R.b<sup>3</sup> are H and L is -(Ph-CH<sub>2</sub>CONH)<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>- , Fl is not fluorescein, NBD or Rhodamine.

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

107. (Previously Presented) The compound of Claim 106 wherein L is selected from a short, medium or long chain moiety and prevents loss of affinity of ligand by distancing the F1 moiety from the Lig moiety, preventing interference with GPCR receptor binding.

108. (Previously Presented) The compound of Claim 106 wherein J<sub>Lm</sub> L J<sub>Tm</sub> comprises a polypeptide, peptide or polyether.

109. (Previously Presented) The compound of Claim 64, having verified pharmacology for binding to or inhibition of a GPCR receptor including measure of affinity or inhibition.

110. (Previously Presented) The compound of Claim 64 having verified pharmacological properties defined in terms of cells expressing a GPCR receptor as hereinbefore defined and given as the Inhibition or Antagonism of receptor binding or of receptor functionality together with a value for the Inhibition (pK<sub>B</sub>) or Antagonism (pK<sub>I</sub>) binding constants, and optionally together with fluorescent images of the pharmacological binding in single living cells illustrating the defined inhibition or antagonism, which are determined by virtue of its Spectral Properties including Excitation Max and Emission Max, Fluorescence Lifetime and Emission quantum yield.

111. (Previously Presented) The compound of Claim 64 having verified pharmacological properties defined in terms of EC<sub>50</sub> values for agonist stimulated – or pK<sub>I</sub> values for antagonism of agonist stimulated second messenger generation.

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

112. (Previously Presented) The compound of Claim 111 wherein pharmacology is defined in terms of a cell or protein wherein the cell expresses a GPCR or the protein is a GPCR.

113. (Previously Presented) The compound of Claim 64 wherein pharmacological properties are given as EC<sub>50</sub> values for agonist stimulated – or pK<sub>i</sub> values for antagonism of agonist stimulated second messenger generation.

114. (Previously Presented) The compound of Claim 110 wherein spectral properties and fluorescent images are derived using the techniques of confocal microscopy or fluorescence correlation spectroscopy.

115. (New) A compound of formula I



or salt thereof wherein an optically active ligand is present as a racemate or as one of its optically active isomers

comprising ligand moiety Lig linked to tag moiety Tag via linker moiety L at linking site or linking functionality J<sub>T</sub> and J<sub>L</sub>

wherein Lig is a ligand selected from a non-peptide GPCR ligand agonist and a non-peptide GPCR ligand antagonist, wherein the Lig comprises pharmacological activity as an agonist or antagonist or GPCR receptor binding and activation or inhibition

L is selected from amine, amide, saturated or unsaturated, substituted or unsubstituted C<sub>1-600</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

selected from N, O, S, P, wherein optional substituents are selected from any C<sub>1-20</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano and carbonyl and combinations thereof, and L is monomeric, oligomeric having oligomeric repeat of 2 to 30 or polymeric having polymeric repeat in excess of 30 up to 300;

m are each independently selected from a whole number integer from 1 to 3;

p is 0 to 3

wherein -Tag is a fluorophore entity -Fl, whereby the compound is of formula I'

(LigJ<sub>L</sub>)<sub>m</sub> L (J<sub>T</sub> Fl)<sub>m</sub> (J<sub>T</sub> L (J<sub>L</sub> Lig)<sub>m</sub>)<sub>p</sub>

wherein Fl is selected from a red or near ir dye and Fl includes a substituent -t- which is a heteroaryl or alkenyl group which performs a fluorescence modifying function which shifts the fluorescence to the red part of the spectrum and raises the absorption max value.

116. (New) The compound of Claim 115, wherein Fl is selected from the EVOBLUE™ oxazine based dyes, the cyanine dyes, the dyomics (DY dyes and ATTO dyes), the Alexafluor dyes, and the 4,4-difluoro-4-bora-3a,4a-diaz-s-indacene dyes.

117. (New) The compound of Claim 115, wherein Fl is selected from 4,4-difluoro-4-bora-3a,4a-diaz-s-indacene dyes.

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

118. (New) The compound of Claim 115, for GPCR binding and measuring fluorescence with time, in both time and concentration dependent manner, wherein the compound shows low background fluorescence.

119. (New) The compound of Claim 115 for GPCR binding and measuring fluorescence with time, in both time and concentration dependent manner, wherein Fl is selected from 4,4-difluoro-4-bora-3a,4a-diaz-s-indacene dyes, wherein the compound shows low background fluorescence.

120. (New) The compound of Claim 115, for use in receptor binding or inhibition, and visualisation by contacting the compound, wherein Fl is a red dye, with a sample in manner to facilitate binding or inhibition thereof, and detecting changes in fluorescence or location thereof by detecting a change in the intensity, excitation or emission wavelength distribution of fluorescence (single or multi photon).

121. (New) The compound of Claim 64, for use in receptor binding or inhibition, and visualisation by contacting the compound, wherein Fl is a blue dye, with a sample in manner to facilitate binding or inhibition thereof, and detecting changes in fluorescence or location thereof by detecting a change in the intensity, excitation or emission wavelength distribution of fluorescence (multi photon)

with the *proviso* that

a) when Lig is 8-[4-[(2-aminoethyl)- aminocarbonylmethoxy]phenyl]-1,3-dipropylxanthine whereby in Lig.a when each of R.a<sup>1</sup> and R.a<sup>2</sup> is propyl, R.a<sup>3</sup> is H and R.a<sup>4</sup> is -

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

Ph-OCH<sub>2</sub>CONH(CH<sub>2</sub>)<sub>2</sub>NH-, and L is gly and n=3 or L is n-chloro succinimide, Fl is not o-(6-hydroxy-3-oxo-3H-xanthen-9-yl) benzoic acid, or

when Lig is 8-[4-[(2-aminoethyl)- aminocarbonylmethoxy]phenyl]-1,3-dipropylxanthine and L is n-chloro succinimide, Fl is not o-(6-hydroxy-3-oxo-3H-xanthen-9-yl) benzoic acid or 7-nitrobenz-2-oxa-1,3-diazole-4-yl;

b) when Lig is adenosine Fl is not Fluorenylmethyloxycarbonyl; or

when Lig is N<sup>6</sup>-[4-[[[4-[[[(2-aminoethyl)amino]carbonyl]methyl]-anilino]carbonyl]methyl]phenyl]adenosine, whereby R.b<sup>1</sup> is CH<sub>2</sub>OH, R.b<sup>2</sup> and R.b<sup>3</sup> are H and L is -(Ph-CH<sub>2</sub>CONH)<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>, Fl is not o-(6-hydroxy-3-oxo-3H-xanthen-9-yl) benzoic acid, 7-nitrobenz-2-oxa-1,3-diazole-4-yl or [9-(2-carboxyphenyl)-6-diethylamino-3-xanthenylidene], or

when Lig is 5'-N-Ethylcarboxamidoadenosine (incorporating the moiety -(CH<sub>2</sub>)<sub>m</sub>) whereby R.b<sup>2</sup> and R.b<sup>3</sup> are H and L is -(CH<sub>2</sub>)<sub>m</sub> when m is 2, 4, 6, 8 or 10 then Fl is not 7-nitrobenz-2-oxa-1,3-diazole-4-yl, or when m is 3, 4, 6, 8, 10 or 12 then Fl is not 5-(dimethylamino)naphthalene-1-sulfonyl, or

when Lig is N<sup>6</sup>-[2-(4-aminophenyl)ethyl]adenosine and L is (CH<sub>2</sub>)<sub>2</sub>-PhNH, Fl is not o-(6-hydroxy-3-oxo-3H-xanthen-9-yl) benzoic acid isothiocyanate;

d) when Lig is (4-(3-tertiarybutylamino-2-hydroxypropoxy)-benzimidazole-2-on hydrochloride) and L (R.d<sup>2</sup>) is mono amine menthane, Fl is not 4,4-difluoro-5,7dimethyl-4-bora-3a,4a-diaza-s-indacene-3-(4-methoxy 1-benzyl), or

when Lig is (4-(3-tertiarybutylamino-2-hydroxypropoxy)-benzimidazole-2-on hydrochloride) and L is 1,1,4,4-tetramethyl butylamine, i.e C(CH<sub>3</sub>)<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>NH- Fl is not 4,4-difluoro-5,7dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid, or when L is

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

C(CH<sub>3</sub>)<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>NHCSNH- then Fl is not o-(6-hydroxy-3-oxo-3H-xanthen-9-yl) benzoic acid isothiocyanate, tetrabromo or dibromo o-(6-hydroxy-3-oxo-3H-xanthen-9-yl) benzoic acid or tetraido o-(6-hydroxy-3-oxo-3H-xanthen-9-yl) benzoic acid; or when L is monoamine menthane, Fl is not o-(6-hydroxy-3-oxo-3H-xanthen-9-yl) benzoic acid isothiocyanate, or when Lig is alprenolol i.e o-prop-2-enyl phenyl and L is -C(CH<sub>3</sub>)<sub>2</sub>-, Fl is not 7-nitrobenz-2-oxa-1,3-diazole-4-yl.

122. (New) The compound of Claim 64,

with the *proviso* that

a) when Lig is 8-[4-[(2-aminoethyl)- aminocarbonylmethoxy]phenyl]-1,3-dipropylxanthine, whereby in Lig.a when each of R.a<sup>1</sup> and R.a<sup>2</sup> is propyl, R.a<sup>3</sup> is H and R.a<sup>4</sup> is -Ph-OCH<sub>2</sub>CONH(CH<sub>2</sub>)<sub>2</sub>NH-, and L is a single bond Fl is not 6-(((4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)styryloxy)acetyl)aminohexanoyl, and

b) when Lig is N6-(4-Aminobutyl)-5'-ethylamino-5'-oxo-5'-deoxyadenosine, whereby m is 4 and L is a single bond Fl is not 6-(((4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)styryloxy)acetyl)aminohexanoyl.

123. (New) The compound of Claim 64,

with the *proviso* that

a) when Lig is 8-[4-[(2-aminoethyl)- aminocarbonylmethoxy]phenyl]-1,3-dipropylxanthine whereby in Lig.a when each of R.a<sup>1</sup> and R.a<sup>2</sup> is propyl, R.a<sup>3</sup> is H and R.a<sup>4</sup> is -

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

Ph-OCH<sub>2</sub>CONH(CH<sub>2</sub>)<sub>2</sub>NH-, and L is gly and n=3 or L is n-chloro succinimide, Fl is not o-(6-hydroxy-3-oxo-3H-xanthen-9-yl) benzoic acid, or

when Lig is 8-[4-[(2-aminoethyl)- aminocarbonylmethoxy]phenyl]-1,3-dipropylxanthine and L is n-chloro succinimide, Fl is not o-(6-hydroxy-3-oxo-3H-xanthen-9-yl) benzoic acid or 7-nitrobenz-2-oxa-1,3-diazole-4-yl;

b) when Lig is adenosine Fl is not Fluorenylmethoxy carbonyl; or

when Lig is N<sup>6</sup>-[4-[[[4-[[[(2-aminoethyl)amino]carbonyl]methyl]-anilino]carbonyl]methyl]phenyl]adenosine, whereby R.b<sup>1</sup> is CH<sub>2</sub>OH, R.b<sup>2</sup> and R.b<sup>3</sup> are H and L is -(Ph-CH<sub>2</sub>CONH)<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>, Fl is not o-(6-hydroxy-3-oxo-3H-xanthen-9-yl) benzoic acid, 7-nitrobenz-2-oxa-1,3-diazole-4-yl or [9-(2-carboxyphenyl)-6-diethylamino-3-xanthenylidene]; or

when Lig is 5'-N-Ethylcarboxamido adenosine (incorporating the moiety -(CH<sub>2</sub>)<sub>m</sub>) whereby R.b<sup>2</sup> and R.b<sup>3</sup> are H and L is -(CH<sub>2</sub>)<sub>m</sub> when m is 2, 4, 6, 8 or 10 then Fl is not 7-nitrobenz-2-oxa-1,3-diazole-4-yl, or when m is 3, 4, 6, 8, 10 or 12 then Fl is not 5-(dimethylamino)naphthalene-1-sulfonyl; or

when Lig is N<sup>6</sup>-[2-(4-aminophenyl)ethyl]adenosine and L is (CH<sub>2</sub>)<sub>2</sub>PhNH, Fl is not o-(6-hydroxy-3-oxo-3H-xanthen-9-yl) benzoic acid isothiocyanate;

d) when Lig is (4-(3-tertiarybutylamino-2-hydroxypropoxy)-benzimidazole-2-on hydrochloride) and L (R.d<sup>2</sup>) is mono amine menthane, Fl is not 4,4-difluoro-5,7dimethyl-4-bora-3a,4a-diaza-s-indacene-3-(4-methoxy 1-benzyl); or

when Lig is (4-(3-tertiarybutylamino-2-hydroxypropoxy)-benzimidazole-2-on hydrochloride) and L is 1,1,4,4-tetramethyl butylamine, i.e C(CH<sub>3</sub>)<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>NH- Fl is not 4,4-difluoro-5,7dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid, or when L is

**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.114(c)**  
**U.S. Application No. 10/551,475 (Q111431)**

C(CH<sub>3</sub>)<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>NHCSNH- then Fl is not o-(6-hydroxy-3-oxo-3H-xanthen-9-yl) benzoic acid isothiocyanate, tetrabromo or dibromo o-(6-hydroxy-3-oxo-3H-xanthen-9-yl) benzoic acid or tetraiodo o-(6-hydroxy-3-oxo-3H-xanthen-9-yl) benzoic acid; or when L is monoamine menthane, Fl is not o-(6-hydroxy-3-oxo-3H-xanthen-9-yl) benzoic acid isothiocyanate; or

when Lig is alprenolol i.e o-prop-2-enyl phenyl and L is -C(CH<sub>3</sub>)<sub>2</sub>, Fl is not 7-nitrobenz-2-oxa-1,3-diazole-4-yl.

124. (New) The compound of Claim 115,

with the *proviso* that

a) when Lig is 8-[4-[(2-aminoethyl)- aminocarbonylmethyloxy]phenyl]-1,3-dipropylxanthine, whereby in Lig.a when each of R.a<sup>1</sup> and R.a<sup>2</sup> is propyl, R.a<sup>3</sup> is H and R.a<sup>4</sup> is -Ph-OCH<sub>2</sub>CONH(CH<sub>2</sub>)<sub>2</sub>NH-, and L is a single bond Fl is not 6-(((4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)styryloxy)acetyl)aminohexanoyl, and

b) when Lig is N6-(4-Aminobutyl)-5'-ethylamino-5'-oxo-5'-deoxyadenosine, whereby m is 4 and L is a single bond Fl is not 6-(((4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)styryloxy)acetyl)aminohexanoyl.